Protein heterodimers and their uses
By developing protein heterodimers containing Fc subunit and IL10, the problems of short half-life of immunomodulators and impurities in the prior art have been solved, and efficient and safe tumor suppression effect is achieved, which is suitable for cancer treatment.
Patent Information
- Application Number
- CN202080024374.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-25
- Filing Date
- 2020-03-24
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-03-24
AI Technical Summary
The prior art is difficult to effectively produce long-acting immunomodulators that maintain a long half-life in the body for the treatment of diseases associated with excessive cell or tissue proliferation, such as cancer, and there is a risk of impurities during the production process.
A protein heterodimer, including Fc subunits and IL10, was developed to form asymmetric dimers through modification and combination of Fc subunits, reducing antibody heavy and light chain variables specific for tumor antigen binding area, improves stability and purity.
A high-yield and long-acting immunomodulators are achieved, which reduces the risk of impurities, enhances the inhibitory effect on tumors, and improves the effectiveness and safety of treatment.
Smart Images

Figure CN113692416B_ABST
Abstract
Description
Background Art
[0001] Although immune responses to tumor antigens can be detected (Disis et al. (1997) J.Clin.Oncol. ("Journal of Clinical Oncology") 15: 3363-3367), malignant cells that cause disease generally do not trigger an immune response that causes rejection. Studies have shown that the immunogenicity of tumor cells can be enhanced by introducing immunomodulatory molecules such as cytokines and co-stimulatory molecules into tumor cells. However, the expression and stability of the introduced immunomodulatory molecules are generally unsatisfactory. Immunomodulatory factors such as cytokines produced by immune system cells can directly or indirectly activate cells with adaptive immune responses and can play an important role in triggering protective anti-tumor immunity. The innate immune system can be triggered by bacterial products or "danger" signals that cause the release of pro-inflammatory cytokines such as IFN-α, TNF-α and interleukins.
[0002] Multiple studies have shown that immunomodulatory factors (such as interleukins) may be suitable for exerting anti-tumor effects in animal models and cancer patients. However, interleukins have a relatively short serum half-life in vivo. For example, as measured by in vitro bioassays or by efficacy in a septic shock model system (see Smith et al., Cellular Immunology ("Cellular Immunology") 173: 207-214 (1996)), the half-life of IL10 in mice is about 2 hours to 6 hours. Interleukin activity loss may be caused by several factors, including renal clearance, proteolytic degradation, and monomerization in the bloodstream.
[0003] Therefore, there is a great need for long-acting immunomodulators that can be produced at relatively high yields on an industrial scale and that will have a relatively long half-life in vivo to be suitable for treating conditions or diseases associated with excessive proliferation of cells and / or tissues (e.g., various neoplasms, different types of cancers and / or tumors). In addition, the yield of such products should be high enough to avoid complex purification processes and / or reduce the risks associated with undesirable impurities. Summary of the Invention
[0004] The present disclosure addresses such needs while providing related advantages. The present disclosure encompasses protein heterodimers suitable for inhibiting tumor growth, as well as compositions, medicaments and / or kits comprising the protein heterodimers. In addition, the present disclosure provides protein mixtures comprising the protein heterodimers and having very few (if any) undesirable impurities (such as undesirable protein homodimers or protein aggregates). The present disclosure also provides methods for producing protein heterodimers or protein mixtures, and pharmaceutical uses of protein heterodimers and / or protein mixtures in inhibiting tumor growth (including but not limited to treating cancer).
[0005] In one aspect, the present disclosure provides a protein heterodimer comprising a first monomer member and a second monomer member different from the first monomer member, wherein: the first monomer member comprises a first Fc subunit, the second monomer member comprises a second Fc subunit, and the first monomer member associates with the second monomer member to form a heterodimer through complexing of the first Fc subunit with the second Fc subunit; wherein the protein heterodimer further comprises one or more IL10s fused directly or indirectly to the carboxyl-terminal amino acids of the first Fc subunit or the second Fc subunit; and wherein the protein heterodimer does not include any antibody heavy chain variable region or any antibody light chain variable region that exhibits binding specificity to a tumor antigen.
[0006] In some embodiments, the first monomer member and the second monomer member form an asymmetric dimer.
[0007] In some embodiments, the protein heterodimer comprises two IL10s fused directly or indirectly to the carboxyl-terminal amino acid of the first Fc subunit or the second Fc subunit.
[0008] In some embodiments, two IL10s are fused directly or indirectly to each other.
[0009] In some embodiments, two IL10s are fused to each other via a peptide linker.
[0010] In some embodiments, the first of the two IL10s is fused directly or indirectly to the carboxyl terminal amino acid of the first or second Fc subunit, and the second of the two IL10s is fused directly or indirectly to the carboxyl terminal amino acid of the first IL10.
[0011] In some embodiments, the one or more IL10s are fused to the carboxy-terminal amino acid of the first Fc subunit or the second Fc subunit via a peptide linker.
[0012] In some embodiments, the first Fc subunit and / or the second Fc subunit are derived from an IgG molecule. In some embodiments, the IgG is selected from IgG1, IgG2, IgG3, and IgG4. In some embodiments, the IgG is human IgG1.
[0013] In some embodiments, the protein heterodimer does not include any targeting moiety that exhibits binding specificity for any tumor antigen.
[0014] In some embodiments, the protein heterodimer does not include any antibody heavy chain variable region or any antibody light chain variable region.
[0015] In some embodiments, the first Fc subunit is different from the second Fc subunit, and the first and / or second Fc subunit comprises a modification that promotes heterodimerization between the first Fc subunit and the second Fc subunit.
[0016] In some embodiments, the first Fc subunit comprises a first modification and the second Fc subunit comprises a second modification.
[0017] In some embodiments, the first modification comprises an amino acid substitution at position T366, and an amino acid substitution at one or more positions selected from the group consisting of: Y349, F405, K409, D399, K360, Q347, K392, and S354, wherein the positions of the amino acids are determined according to the EU index with KABAT numbering.
[0018] In some embodiments, the first modification comprises an amino acid substitution selected from the group consisting of Y349C, Y349D, D399S, F405K, K360E, K409A, K409E, Q347E, Q347R, S354D, K392D, and T366W, wherein the positions of amino acids are determined according to the EU index with KABAT numbering.
[0019] In some embodiments, the first modification comprises 2 to 5 amino acid substitutions.
[0020] In some embodiments, the first modification comprises an amino acid substitution at a group of positions selected from any one of the following groups: 1) Y349 and T366; 2) Y349, T366, and F405; 3) Y349, T366, and K409; 4) Y349, T366, F405, K360, and Q347; 5) Y349, T366, F405, and Q347; 6) Y349, T366, K409, K360, and Q347; 7) Y349, T366, K409 and Q347; 8) T366, K409 and K392; 9) T366 and K409; 10) T366, K409, Y349 and S354; 11) T366 and F405; 12) T366, F405 and D399; and 13) T366, F405, Y349 and S354; wherein the positions of the amino acids are determined according to the EU index with KABAT numbering.
[0021] In some embodiments, the first modification comprises a set of amino acid substitutions selected from any one of the following groups: 1) Y349C and T366W; 2) Y349C, T366W, and F405K; 3) Y349C, T366W, and K409E; 4) Y349C, T366W, and K409A; 5) Y349C, T366W, F405K, K360E, and Q347E; 6) Y349C, T366W, F405K, and Q347R; 7) Y349C, T366W, K409A, K360E, and Q347E; 8) Y349C, T366W, K409A and Q347R; 9) T366W, K409A and K392D; 10) T366W and K409A; 11) T366W, K409A and Y349D; 12) T366W, K409A, Y349D and S354D; 13) T366W and F405K; 14) T366W, F405K and D399S; 15) T366W, F405K and Y349D; and 16) T366W, F405K, Y349D and S354D; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0022] In some embodiments, the second modification comprises an amino acid substitution at positions T366, L368, and Y407, and an amino acid substitution at one or more positions selected from the group consisting of D356, D399, E357, F405, K360, K392, K409, and Q347, wherein the positions of amino acids are determined according to the EU index with KABAT numbering.
[0023] In some embodiments, the second modification comprises an amino acid substitution selected from the group consisting of D356C, D399S, E357A, F405K, K360E, K392D, K409A, L368A, L368G, Q347E, Q347R, T366S, Y407A, and Y407V, wherein the amino acid positions are determined according to the EU index with KABAT numbering.
[0024] In some embodiments, the second modification comprises 4 to 6 amino acid substitutions.
[0025] In some embodiments, the second modification comprises an amino acid substitution at a group of positions selected from any one of the following groups: 1) D356, T366, L368, Y407, and F405; 2) D356, T366, L368, and Y407; 3) D356, T366, L368, Y407, and Q347; 4) D356, T366, L368, Y407, K360, and Q347; 5) D356, T366, L368, Y407, F405, and 7) T366, L368, Y407, F405, K360, and Q347; 8) T366, L368, Y407, and F405; 9) T366, L368, Y407, F405, and E357; 10) T366, L368, Y407, and K409; 11) T366, L368, Y407, K409, and K392; and 12) T366, L368, Y407, K409, and E357; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0026] In some embodiments, the second modification comprises an amino acid substitution at a group of positions selected from any one of the following groups: 1) D356C, T366S, L368A, Y407V, and F405K; 2) D356C, T366S, L368A, and Y407V; 3) D356C, T366S, L368A, Y407V, and Q347R; 4) D356C, T366S, L368A, Y407V, K360E, and Q347E; 5) D356C, T366S, L368A, Y407V, F405K, and Q347R; 6) D356C, T366S, L368A, Y407V, F405K, K360E, and Q347R. 47E; 7) T366S, L368A, Y407V, D399S and F405K; 8) T366S, L368G, Y407A and F405K; 9) T366S, L368A, Y407V, F405K and E357A; 10) T366S, L368A, Y407V and K409A; 11) T366S, L368A, Y407V, K409A and K392D; 12) T366S, L368G, Y407A and K409A; 13) T366S, L368A, Y407V, K409A and E357A; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0027] In some embodiments, the first Fc subunit comprises a first modification, the second Fc subunit comprises a second modification, and the first modification and the second modification comprise amino acid substitutions at a group of positions selected from any one of the following groups: 1) first modification: Y349 and T366; and second modification: D356, T366, L368, Y407, and F405; 2) first modification: Y349, T366, and F405; and second modification: D356, T366, L368, and Y407; 3) first modification: Y349, T366, and K409; and second modification: D356, T366, L368, Y407, and F405; 4) first modification: Y349, T366, and K409; and second modification: D356, T366, L368, Y407, and F405. 66, F405, K360 and Q347; and second modification: D356, T366, L368, Y407 and Q347; 5) first modification: Y349, T366, F405 and Q347; and second modification: D356, T366, L368, Y407, K360 and Q347; 6) first modification: Y349, T366, K409, K360 and Q347; and second modification: D356, T366, L368, Y407, F405 and Q347; 7) first modification: Y349, T366, K409 and Q347; and second modification: D356, T366, L368, Y407 , F405, K360 and Q347; 8) first modification: T366, K409 and K392; and second modification: T366, L368, Y407, D399 and F405; 9) first modification: T366 and K409; and second modification: T366, L368, Y407 and F405; 10) first modification: T366, K409 and Y349; and second modification: T366, L368, Y407, F405 and E357; 11) first modification: T366, K409, Y349 and S354; and second modification: T366, L368, Y407, F405 and E357; 12) first modification : T366 and F405; and the second modification: T366, L368, Y407 and K409; 13) the first modification: T366, F405 and D399; and the second modification: T366, L368, Y407, K409 and K392; 14) the first modification: T366, F405 and Y349; and the second modification: T366, L368, Y407, K409 and E357; 15) the first modification: T366, F405, Y349 and S354; and the second modification: T366, L368, Y407, K409 and E357; wherein the positions of the amino acids are determined according to the EU index of KABAT numbering.
[0028] In some embodiments, the first Fc subunit comprises a first modification and the second Fc subunit comprises a second modification, wherein the first modification and the second modification comprise a set of amino acid substitutions selected from any one of the following groups: 1) first modification: Y349C and T366W; and second modification: D356C, T366S, L368A, Y407V, and F405K; 2) first modification: Y349C, T366W, and F405K; and second modification: D356C, T366S, L368A, and Y407V; 3) first modification: Y349C, T366W, and K409E; and second modification: D356C, T366S, L368A, Y407V, and F405K; 4) first modification: Y349C, T366W, and K409A; and second modification: D356C, T366S, L368A, Y407V, and F405K; 5) first modification: Y349C, T366W, F405K, K360E, and Q347E; and second modification: D356C, T366S, L368A, Y407V, and Q347R; 6) first modification: Y349C, T366W, F405K, and Q347R; and second modification: D356C, T366S, L368A, Y407V, K360E, and Q347E; 7) first modification: Y349C, T366W, K409A, K360E, and Q347E; and second modification: D 356C, T366S, L368A, Y407V, F405K and Q347R; 8) first modification: Y349C, T366W, K409A and Q347R; and second modification: D356C, T366S, L368A, Y407V, F405K, K360E and Q347E; 9) first modification: T366W, K409A and K392D; and second modification: T366S, L368A, Y407V, D399S and F405K; 10) first modification: T366W and K409A; and second modification: T366S, L368G, Y407A and F405K; 11) first modification: T366W, K409 A and Y349D; and second modification: T366S, L368A, Y407V, F405K and E357A; 12) first modification: T366W, K409A, Y349D and S354D; and second modification: T366S, L368A, Y407V, F405K and E357A; 13) first modification: T366W and F405K; and second modification: T366S, L368A, Y407V and K409A; 14) first modification: T366W, F405K and D399S; and second modification: T366S, L368A, Y407V, K409A and K392D; 15) first modification: T366W and F405K;and a second modification: T366S, L368G, Y407A, and K409A; 16) a first modification: T366W, F405K, and Y349D; and a second modification: T366S, L368A, Y407V, K409A, and E357A; 17) a first modification: T366W, F405K, Y349D, and S354D; and a second modification: T366S, L368A, Y407V, K409A, and E357A; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0029] In some embodiments, the first Fc subunit comprises a first modification and the second Fc subunit comprises a second modification, the first modification comprises amino acid substitutions T366W and K409A, and the second modification comprises amino acid substitutions T366S, L368G, Y407A, and F405K, wherein the positions of amino acids are determined according to the EU index with KABAT numbering.
[0030] In some embodiments, at least one of the one or more IL10s is fused directly or indirectly to a second Fc subunit.
[0031] In some embodiments, at least one of the one or more IL10s is fused directly or indirectly to the carboxy-terminal amino acid of the second Fc subunit.
[0032] In some embodiments, the second monomer member includes two IL10s, a first IL10 of the two IL10s fused directly or indirectly to the carboxyl terminal amino acid of the second Fc subunit, and a second IL10 of the two IL10s fused directly or indirectly to the carboxyl terminal amino acid of the first IL10.
[0033] In some embodiments, the first monomer member does not include any IL10.
[0034] In some embodiments, the first monomer member consists of the first Fc subunit.
[0035] In some embodiments, the second monomer member consists of one IL10 fused directly or through a peptide linker to the carboxy-terminal amino acid of the second Fc subunit.
[0036] In some embodiments, the second monomer member is composed of two IL10s fused to a second Fc subunit directly or via a peptide linker, wherein a first IL10 of the two IL10s is fused directly to the carboxyl-terminal amino acid of the second Fc subunit or via a peptide linker, and the second IL10 of the two IL10s is fused directly to the carboxyl-terminal amino acid of the first IL10 or via a peptide linker.
[0037] In some embodiments, the amino acid sequence of the second monomer member is shown in any one of SEQ ID NO.18, NO.38, NO.53, NO.55, NO.60 and NO.62.
[0038] In some embodiments, the amino acid sequence of the first monomer member is as shown in any one of SEQ ID NO. 17 and NO. 57.
[0039] In another aspect, the present disclosure provides one or more isolated nucleic acids encoding a protein heterodimer according to the present disclosure.
[0040] In another aspect, the present disclosure provides one or more vectors comprising one or more isolated nucleic acids according to the present disclosure.
[0041] In another aspect, the present disclosure provides an isolated host cell comprising one or more isolated nucleic acids according to the present disclosure or one or more vectors according to the present disclosure.
[0042] On the other hand, the present disclosure provides a protein mixture comprising: 1) a protein heterodimer according to the present disclosure; 2) a first homodimer formed by two identical copies of a first monomer member according to the present disclosure; and 3) a second homodimer formed by two identical copies of a second monomer member according to the present disclosure; wherein the percentage of the protein heterodimers in the protein mixture is at least 50%.
[0043] In some embodiments, the percentage of the second homodimer is less than the percentage of the first homodimer.
[0044] In some embodiments, the percentage of the second homodimer is at most 10%.
[0045] In some embodiments, the protein mixture comprises substantially no second homodimer.
[0046] In some embodiments, the protein mixture is produced directly by the host cell without enrichment for protein heterodimers and / or depletion of the first or second homodimers.
[0047] In another aspect, the present disclosure provides a pharmaceutical composition comprising the protein heterodimer according to the present disclosure, or the protein mixture according to the present disclosure, and optionally a pharmaceutically acceptable excipient.
[0048] In some embodiments, the protein heterodimer is formulated for oral administration, intravenous administration, intramuscular administration, in situ administration at a tumor site, inhalation, rectal administration, vaginal administration, transdermal administration, or administration via a subcutaneous depot.
[0049] In another aspect, the present disclosure provides a use of the protein heterodimer according to the present disclosure or the protein mixture according to the present disclosure for preparing a medicament and / or a kit for inhibiting the growth of tumors or tumor cells.
[0050] In another aspect, the present disclosure provides a use of a protein heterodimer according to the present disclosure or a protein mixture according to the present disclosure for the preparation of a medicament for treating cancer in a subject in need thereof.
[0051] In another aspect, the present disclosure provides a method for inhibiting the growth of a tumor or tumor cells, comprising contacting the tumor or tumor cells with an effective amount of a protein heterodimer according to the present disclosure or a protein mixture according to the present disclosure.
[0052] In some embodiments, the contacting is performed in vitro or in vivo.
[0053] In another aspect, the present disclosure provides a method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a protein heterodimer according to the present disclosure or a protein mixture according to the present disclosure.
[0054] On the other hand, the present disclosure provides a method for producing a protein heterodimer according to the present disclosure, which comprises (i) culturing a host cell according to the present disclosure under conditions that achieve expression of the protein heterodimer, and (ii) harvesting the expressed protein heterodimer or a protein mixture comprising the protein heterodimer.
[0055] Those skilled in the art can easily discern other aspects and advantages of the present application from the detailed description below. In the detailed description below, only exemplary embodiments of the present application are shown and described. As will be appreciated by those skilled in the art, the content of this application enables those skilled in the art to modify the disclosed specific embodiments without departing from the spirit and scope of the invention to which this application relates. Accordingly, the descriptions in the drawings and specification of this application are merely exemplary and not restrictive.
[0056] Incorporated by Reference
[0057] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] The specific features of the invention involved in this application are shown in the appended claims. The features and advantages of the invention involved in this application can be better understood by referring to the exemplary embodiments described in detail below and the accompanying drawings. A brief description of the drawings is as follows:
[0059] Figure 1 A to Figure 1 E shows an example of a protein heterodimer according to the present application.
[0060] Figures 2A to 2G Shown are the purification results of protein heterodimers of the present disclosure as shown by SDS-PAGE and SEC-HPLC analysis.
[0061] Figure 3 The binding affinity to human IL10R1 protein is shown (ELISA).
[0062] Figures 4A to 4C Enhancement of proliferation of MC / 9 cells was shown.
[0063] Figure 5 Inhibition of TNF-α secretion is shown.
[0064] Figures 6A to 6B The tumor controlling effect of the protein heterodimers of the present disclosure is shown.
[0065] 7A to 7B Shown are comparisons between high and low concentrations of protein heterodimers in tumor control as well as comparisons between the tumor control effects of protein heterodimers and protein homodimers.
[0066] Figures 8A to 8B The tumor control and tumor clearance effects of the protein heterodimers of the present disclosure are shown. DETAILED DESCRIPTION
[0067] The following describes the implementation of the present invention through specific embodiments. People familiar with this technology can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0068] Before describing the embodiments of the present disclosure, it should be understood that these embodiments are provided by way of example only, and various alternatives of the embodiments of the present disclosure described herein can be used to practice the present disclosure. Those skilled in the art will think of numerous variations, changes and substitutions that do not depart from the present disclosure.
[0069] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which this application belongs. Although methods and materials similar or equivalent to those described herein can be used to practice or test the present disclosure, suitable methods and materials are described below. In the event of a conflict, this patent specification (including definitions) will be taken as the criterion. In addition, materials, methods and embodiments are only illustrative and have no restrictive intention. Those skilled in the art will appreciate that numerous variations, changes and replacements do not depart from the present disclosure.
[0070] As used herein, the singular forms "a," "an," and "the" generally include plural referents unless the context clearly dictates otherwise.
[0071] As used herein, the term "proteinaceous" generally refers to a material or molecule that has the properties of, is related to, resembles, or is a polypeptide or protein. For example, a protein heterodimer of the present disclosure can be a heterodimeric protein or a heterodimer comprising two or more polypeptides.
[0072] As used herein, the term "heterodimer" generally refers to a molecule (e.g., a protein molecule) composed of two different members. The two members of a heterodimer may differ in structure, function, activity, and / or composition. For example, the two different members may comprise polypeptides that differ in the order, number, or type of amino acid residues that form the polypeptide. Each of the two different members of a heterodimer may individually comprise one, two, or more units, polypeptide chains, or portions.
[0073] As used herein, the term "targeting moiety" generally refers to a molecule, complex or aggregate that specifically, selectively or preferentially binds to a target molecule, target cell, target particle, target tissue or target aggregate. For example, the targeting moiety can be an antibody, an antigen-binding antibody fragment, a bispecific antibody or other antibody-based molecules or compounds. Other examples of targeting moieties can include but are not limited to aptamers, high-affinity polymers, receptor binding ligands, nucleic acids, biotin-avidin binding pairs, binding peptides or binding proteins, etc. The terms "targeting moiety" and "binding moiety" are used interchangeably herein.
[0074] As used herein, the term "tumor antigen" generally refers to an antigenic substance produced in or by a tumor cell, which may have the ability to trigger an immune response in the host. For example, a tumor antigen can be a protein, polypeptide, peptide, or fragment thereof that constitutes a part of a tumor cell and is capable of inducing tumor-specific cytotoxic T lymphocytes. Tumor antigen peptides can be peptides produced due to degradation of tumor antigens in tumor cells, and when expressed on the cell surface by binding to HLA molecules, can induce or activate tumor-specific cytotoxic T lymphocytes. In some embodiments, the term "tumor antigen" can also refer to a biological molecule (e.g., protein, carbohydrate, glycoprotein, etc.) that is exclusively or preferentially or differentially expressed on cancer cells and / or is found to be associated with cancer cells, thereby providing a preferential or specific target for cancer. For example, preferential expression can be preferential expression compared to any other cell in an organism, or preferential expression in a specific region of an organism (e.g., within a specific organ or tissue).
[0075] The terms "tumor antigen epitope" and "tumor antigen determinant" are used interchangeably herein and generally refer to sites of amino acid sequences present in tumor antigens that induce tumor-specific cytotoxic T lymphocytes.
[0076] As used herein in the context of protein heterodimers, the term "expression yield" generally refers to the amount of protein heterodimer produced in a functional form upon expression (eg, when expressed by a host cell).
[0077] As used herein, the term "dimerization sequence" generally refers to an amino acid sequence that can form a dimer or dimerize. In some embodiments, a dimer is a heterodimer formed by two different members. In some cases, the two different members of a heterodimer can include different dimerization sequences.
[0078] As used herein, the term "heterodimerization" generally refers to the process by which a heterodimer is formed between two different members (e.g., two different polypeptides), such as by complexing, association, or aggregation, with or without the formation of a covalent bond between the two different members.
[0079] As used herein, the term "covalent bond" generally refers to a chemical bond formed between atoms by sharing electrons. For example, a covalent bond can be polar or non-polar. In some embodiments, the covalent bond is a disulfide bond.
[0080] As used herein, the term "non-covalent pair-wise affinity" generally refers to dimerization sequences or heterodimerization sequences that are capable of binding to each other via non-covalent interactions, for example, via ion pairs, hydrogen bonds, dipole interactions, charge transfer interactions, π-π interactions, cation-π-electron interactions, van der Waals interactions, as well as dispersion interactions, hydrophobic (lipophilic) interactions, complex formation (e.g., complex formation with transition metal cations), or a combination of these interactions.
[0081] As used herein, the term "linker" generally refers to a synthetic amino acid sequence that connects or links two polypeptide sequences (e.g., links two polypeptide domains). A linker can connect two amino acid sequences via a peptide bond. In some embodiments, a linker of the present disclosure connects a biologically active portion to a second portion in a linear sequence.
[0082] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. A polymer may be linear or branched, may include modified amino acids, and may be interrupted by non-amino acids. The terms also encompass amino acid polymers that have been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other treatment, such as conjugation with a labeling component. The terms may be applied to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids, as well as to naturally occurring amino acid polymers. The terms may also encompass variants of the traditional peptide bonds that join amino acids to form a polypeptide. For example, "peptide," "polypeptide," and "protein" may be a chain of amino acids whose alpha carbons are linked by peptide bonds. Thus, the terminal amino acid at one end (amino terminus) of the chain may have a free amino group, while the terminal amino acid at the other end (carboxyl terminus) of the chain may have a free carboxyl group. As used herein, the term "amino terminus" (abbreviated as N-terminus) generally refers to the free alpha amino group on the amino acid at the amino terminus of a peptide or refers to the alpha amino group (imino group participating in a peptide bond) of an amino acid at any other position within the peptide. Similarly, the term "carboxyl terminus" generally refers to the free carboxyl group on the carboxyl terminus of a peptide or the carboxyl group of an amino acid at any other position within the peptide. A peptide may also comprise essentially any polyamino acid, including but not limited to peptidomimetics, such as amino acids joined by ether rather than amide bonds.
[0083] As used herein, the term "amino acid" generally refers to natural and / or unnatural or synthetic amino acids, including but not limited to D or L optical isomers or both, amino acid analogs and peptide mimetics. Amino acids are named using standard single-letter or three-letter codes.
[0084] As used herein, the term "natural L amino acids" generally refers to the L optical isomer forms of glycine (G), proline (P), alanine (A), valine (V), leucine (L), isoleucine (I), methionine (M), cysteine (C), phenylalanine (F), tyrosine (Y), tryptophan (W), histidine (H), lysine (K), arginine (R), glutamine (Q), asparagine (N), glutamic acid (E), aspartic acid (D), serine (S), and threonine (T).
[0085] As used herein, the term "non-naturally occurring" generally refers to a polypeptide or polynucleotide sequence that does not correspond to, is not complementary to, or does not have a high degree of homology with a wild-type or naturally occurring sequence (e.g., those found in a subject). For example, when suitable for alignment, a non-naturally occurring polypeptide or fragment can have less than 99%, 98%, 95%, 90%, 80%, 70%, 60%, 50% or even lower amino acid sequence identity with a native sequence. Alternatively, when suitable for alignment, a non-naturally occurring polypeptide or fragment can have greater than 99%, 98%, 95%, 90%, 80%, 70%, 60%, 50% or even higher amino acid sequence identity with a native sequence.
[0086] As used herein, the terms "hydrophilicity" and "hydrophobicity" generally refer to a substance's affinity for water. Hydrophilic substances have a strong affinity for water and tend to dissolve in, mix with, or be wetted by water, whereas hydrophobic substances have essentially no affinity for water, tend to repel and not absorb water, and tend not to dissolve in, mix with, or be wetted by water. Amino acids can be characterized based on their hydrophobicity. Several metrics have been developed. For example, a metric developed by Levitt, M. et al. in J Mol Biol (1976) 104:59 is listed in Hopp, TP. et al., Proc Natl Acad Sci USA (1981) 78:3824. Examples of "hydrophilic amino acids" are arginine, lysine, threonine, alanine, asparagine, and glutamine. Of particular interest are the hydrophilic amino acids aspartate, glutamate, as well as serine and glycine. Examples of "hydrophobic amino acids" are tryptophan, tyrosine, phenylalanine, methionine, leucine, isoleucine and valine.
[0087] The term "fragment" used in the context of a protein molecule (eg, a polypeptide or protein) generally refers to a truncated form of a native biologically active protein that may or may not retain a portion having therapeutic and / or biological activity.
[0088] The term "variant" as used in the context of a protein molecule (e.g., a polypeptide or protein) generally refers to a protein molecule having sequence homology to a native biologically active protein that retains at least a portion of the biologically active protein having therapeutic activity and / or biological activity. For example, a variant protein may have at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity with a reference biologically active protein. In some embodiments, a "variant" may comprise a protein that has been intentionally modified, for example, by site-directed mutagenesis, encoding gene synthesis, insertion, or randomly modified by mutation.
[0089] The terms "conjugated," "linked," and "fused" are used interchangeably herein and generally refer to two or more chemical elements, sequences, or components joined together, for example, by a process comprising chemical conjugation or recombinant means. For example, a promoter or enhancer is operably linked to a coding sequence when it enables transcription of the coding sequence. Typically, "operably linked" means that the linked DNA sequences are continuous and in reading phase or frame. "In-frame fusion" refers to the joining of two or more open reading frames (ORFs) to form a connected longer ORF in a manner that maintains the correct reading frame of the original ORFs. Thus, the resulting "fusion polypeptide" is a single protein containing two or more fragments corresponding to polypeptides encoded by the original ORFs that would not normally be joined in this manner in nature. A "fusion site" refers to the sequence at which two or more fragments are joined together. In some cases, a fusion site can be a sequence that is consistent with a sequence in the two or more joined fragments. In some cases, a fusion site can further include an empty segment that is inconsistent with the sequence of any one of the two or more joined fragments.
[0090] In the context of polypeptides, a "linear sequence" or "sequence" is the order of amino acids in a polypeptide in the amino-terminal to carboxyl-terminal direction, wherein the residues immediately adjacent to each other in the sequence are contiguous in the primary structure of the polypeptide. A "partial sequence" is a linear sequence that forms part of a polypeptide that is known to include additional residues in one or both directions.
[0091] The terms "polynucleotide," "nucleic acid," "nucleotide," and "oligonucleotide" are used interchangeably herein and generally refer to a polymeric form of nucleotides of any length, i.e., deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. The following are non-limiting examples of polynucleotides: coding or non-coding regions of genes or gene fragments, gene positions (locus) defined according to linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA with any sequence, isolated RNA with any sequence, nucleic acid probes, and primers. Polynucleotides can include modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure can be given before or after polymer assembly. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotides can be further modified after polymerization, such as by being conjugated to a labeling component.
[0092] The terms "gene" and "gene fragment" are used interchangeably herein and generally refer to a polynucleotide containing at least one open reading frame that can encode a specific protein after transcription and translation. A gene or gene fragment can be genomic or cDNA, as long as the polynucleotide contains at least one open reading frame that can cover the entire coding region or a segment thereof. A "fusion gene" is a gene composed of at least two heterologous polynucleotides linked together.
[0093] As used herein, the term "antibody" generally refers to a protein comprising one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. Immunoglobulin genes can include κ, λ, α, γ, δ, ε and μ constant region genes and countless immunoglobulin variable region genes. As used herein, light chains can be classified as κ light chains or λ light chains. Heavy chains can be classified as γ, μ, α, δ or ε heavy chains, which in turn define immunoglobulin classes IgG, IgM, IgA, IgD and IgE, respectively. Antibodies as used in the present disclosure can have a structural unit comprising a tetramer. Each tetramer can be composed of two identical polypeptide chain pairs, each pair having a "light" chain (about 25kd) and a "heavy" chain (about 50 to 70kd). The N-terminus of each chain can define a variable region having about 100 to 110 or more amino acids primarily responsible for antigen recognition. As used herein, the terms "light chain variable region" (VL) and "heavy chain variable region" (VH) generally refer to the aforementioned regions of the light chain and heavy chain, respectively. Antibodies may exist as intact immunoglobulins or in a number of well-characterized fragments produced by digestion with various peptidases or re-expressed. Thus, for example, pepsin can digest antibodies below the disulfide bonds in the hinge region to produce F(ab)'2 (a dimer of Fab, which itself is a light chain linked to VH-CH1 via a disulfide bond). F(ab)'2 can be reduced under mild conditions to break the disulfide bonds in the hinge region, thereby converting the (Fab')2 dimer into a Fab' monomer. The Fab' monomer is essentially a Fab with a partial hinge region (for a more detailed description of other antibody fragments, see Fundamental Immunology, ed. W.E. Paul, Raven Press, NY (1993)). Although various antibody fragments are defined based on digestion of intact antibodies, one of ordinary skill in the art will appreciate that these Fab' fragments can be synthesized de novo chemically or by utilizing recombinant DNA methods. Therefore, as used herein, the term antibody may also include antibody fragments produced by modifying whole antibodies or synthesized de novo using recombinant DNA methods, including but not limited to Fab'2, IgG, IgM, IgA, IgE, scFv, dAb, nanobody, single antibody (unibody) and double antibody (diabody). In some embodiments, the above antibodies include but are not limited to Fab'2, IgG, IgM, IgA, IgE and single-chain antibodies, such as single-chain Fv (scFv) antibodies in which a variable heavy chain and a variable light chain are joined together (directly or through a peptide linker) to form a linked polypeptide.
[0094] As used herein, the term "antigen binding site" or "binding portion" generally refers to the part of an antibody that participates in antigen binding. The antigen binding site can be formed by amino acid residues in the N-terminal variable ("V") region of the heavy ("H") chain and / or light ("L") chain. The three highly different segments within the V region of the heavy and light chains are referred to as "hypervariable regions," which are inserted between a plurality of conserved flanking segments called "framework regions" or "FRs." Therefore, as used herein, the term "FR" generally refers to the amino acid sequence found between and near the hypervariable regions in immunoglobulins naturally. In an antibody molecule, the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are arranged relative to each other in three-dimensional space to form an antigen binding "surface." This surface can mediate the recognition and binding of the target antigen. Each of the three hypervariable regions in the heavy and light chains is called a "complementarity determining region" or "CDR" and is characterized, for example, by Kabat et al. Sequences of proteins of immunological interest, 4th ed. U.S. Department of Health and Human Services, Public Health Service, Bethesda, MD (1987).
[0095] As used herein, the term "host cell" generally includes individual cells, cell lines or cell cultures that can accept or have accepted a subject plasmid or vector, including polynucleotides of the present disclosure or expressing protein heterodimers (e.g., heterodimeric proteins) of the present disclosure. Host cells may include offspring of a single host cell. The above-mentioned offspring may not necessarily be completely consistent with the original parent cell (in terms of morphology or in terms of the genome complemented by total DNA) due to natural, accidental or intentional mutations. Host cells may include cells transfected in vitro with the vector of the present disclosure. Host cells may be bacterial cells (e.g., Escherichia coli), yeast cells or other eukaryotic cells, such as COS cells, Chinese hamster ovary (CHO) cells, HELA cells, HEK293 cells, COS-1 cells, NS0 cells or myeloma cells. In some embodiments, host cells are mammalian cells. In some embodiments, host cells are HEK293 cells.
[0096] As used herein, the term "vector" generally refers to a nucleotide molecule capable of self-replication in an appropriate host, which transfers the inserted nucleotide molecule into a host cell and / or between host cells. The term can include vectors primarily used to insert DNA or RNA into cells, vector replication primarily used to replicate DNA or RNA, and expression vectors for transcribing and / or translating DNA or RNA. It also includes vectors that provide more than one of the above functions. An "expression vector" is a polynucleotide that can be transcribed and translated into a polypeptide when introduced into an appropriate host cell. An "expression system" generally means a suitable host cell containing an expression vector that can be used to produce a desired expression product.
[0097] The term "effective amount" or "therapeutically effective amount" refers to an amount of a composition (e.g., a protein heterodimer described herein) sufficient to achieve the intended application (including but not limited to disease treatment). The therapeutically effective amount can vary depending on the intended application (e.g., in vitro or in vivo) or the individual being treated and the disease condition (e.g., the weight and age of the individual, the severity of the disease condition, the mode of administration, etc., which can be readily determined by one of ordinary skill in the art). The term may also apply to a dose that will induce a specific response in the target cell (e.g., target gene induction, proliferation and / or apoptosis). The specific dosage will vary depending on the specific compound selected, the dosing regimen followed, whether it is administered in combination with other compounds, the time of administration, the tissue to which it is administered, and the physical delivery system used to carry it.
[0098] The terms "treatment" or "treating" or "palliating" or "ameliorating" are used interchangeably herein and refer to an approach to obtaining a beneficial or desired result, including but not limited to a therapeutic benefit and / or a prophylactic benefit. As used herein, a therapeutic benefit generally refers to the eradication or reduction in severity of the underlying condition being treated. Moreover, a therapeutic benefit is achieved by eradicating, reducing the severity, or reducing the incidence of one or more physiological symptoms associated with the underlying condition such that an improvement is observed in the subject, although the subject may still be suffering from the underlying condition. For a prophylactic benefit, a composition can be administered to a subject at risk for a particular disease or to a subject who reports one or more physiological symptoms of a disease but may not have been diagnosed with the disease.
[0099] As used herein, the term "therapeutic effect" generally encompasses therapeutic benefits and / or prophylactic benefits as described above. A prophylactic benefit comprises delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, stopping, or reversing the progression of a disease or condition, or any combination thereof.
[0100] As used herein, the term "pharmaceutical" or "bioactive agent" generally refers to a biological, pharmaceutical or chemical compound or other moiety. Non-limiting examples include simple or complex organic or inorganic molecules, peptides, proteins, oligonucleotides, antibodies, antibody derivatives, antibody fragments, vitamin derivatives, carbohydrates, toxins or chemotherapeutic compounds. Various compounds can be synthesized, such as small molecules and oligomers (e.g., oligopeptides and oligonucleotides) and synthetic organic compounds based on various core structures. In addition, various natural sources can provide compounds for screening such as plant or animal extracts.
[0101] As used herein, the term "cell proliferation" generally refers to the phenomenon in which the number of cells changes due to division. For example, cell proliferation can cause an increase in cell number. This term also encompasses cell growth in which changes in cell morphology (e.g., increase in size) are consistent with proliferation signals.
[0102] As used herein, the term "in vivo" generally refers to events that occur inside the body of a subject.
[0103] As used herein, the term "in vitro" generally refers to an event that occurs outside the body of a subject. For example, an in vitro assay encompasses any assay performed outside a subject. In vitro assays encompass cell-based assays that employ dead or live cells. In vitro assays also encompass cell-free assays that do not employ intact cells.
[0104] As used herein, the term "interleukin" generally refers to a secretory protein or signaling molecule that promotes the development and differentiation of T and / or B lymphocytes and / or hematopoietic cells. Interleukins can be synthesized by helper CD4 T lymphocytes and by monocytes, macrophages, and endothelial cells. As used herein, interleukin (il) may include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL -18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35 and / or IL-36. As used herein, the term "interleukin" can include a full-length interleukin or a fragment (e.g., a truncated form) or variant thereof that substantially maintains the biological activity of the corresponding wild-type interleukin (e.g., a biological activity having at least 80%, at least 90%, at least 95%, at least 98%, at least 99% or even at least 100% of the biological activity of the corresponding wild-type interleukin. As used herein, the interleukin can be derived from any mammalian species. In some embodiments, the interleukin is derived from a species selected from the group consisting of humans, horses, cattle, rodents, pigs, rabbits, cats, dogs, rats, goats, sheep, and non-human primates. In some embodiments, the interleukin can be in a mutated form, for example, with an increased or decreased affinity for its receptor. In a specific embodiment, the interleukin may be super-IL-2 (also known as sIL2, see Nature 484, 529–533, April 26, 2012), which can be obtained by modifying IL-2 to increase its binding affinity for IL-2Rβ. Mutations in sIL-2 are primarily in the core of the cytokine, and molecular dynamics simulations indicate that evolved mutations stabilize IL-2, reducing the flexibility of the helices in the IL-2Rβ binding site to an optimized receptor-binding conformation similar to that observed when bound to CD25. Compared to IL-2, sIL-2 induces superior expansion of cytotoxic T cells, resulting in enhanced anti-tumor responses in vivo. sIL-2 also causes a proportional reduction in the expansion of T regulatory cells and reduces pulmonary edema.
[0105] As used herein, the term "subject" generally refers to a human or non-human animal, including but not limited to a cat, dog, horse, pig, cow, sheep, goat, rabbit, mouse, rat, or monkey.
[0106] The term "inhibit growth and / or proliferation" when applied to cancer cells generally refers to reducing the growth rate and / or proliferation rate of cancer cells. For example, this term can include the death of cancer cells (e.g., via apoptosis). In some embodiments, this term can also refer to inhibiting the growth and / or proliferation of solid tumors and / or inducing a decrease in tumor size or elimination of tumors.
[0107] As used herein, the term "cancer cell surface marker" or "cancer cell-associated marker" generally refers to a biological molecule (e.g., protein, carbohydrate, glycoprotein, etc.) that is exclusively, preferentially, or differentially expressed on cancer cells and / or found associated with cancer cells, thereby providing a preferential or specific target for cancer. In some embodiments, preferential expression can be preferential expression compared to any other cell in an organism, or preferential expression in a specific region of an organism (e.g., a specific organ or tissue).
[0108] As used herein, the term "monomeric member" generally refers to a polypeptide, subunit, or moiety that exists in monomeric form and is a component / subunit of a protein heterodimer.
[0109] As used herein, the term "Fc subunit" generally refers to the carboxyl terminal portion of the constant region of an immunoglobulin heavy chain that is capable of binding to an Fc receptor, or an analog or portion thereof. As is well known, each immunoglobulin heavy chain constant region includes four or five domains. The domains are named in sequence as follows: CH1-hinge-CH2-CH3 (-CH4). CH4 exists in the form of IgM, which does not have a hinge region. The immunoglobulin heavy chain constant region used in the present disclosure may include an immunoglobulin hinge region and may also include a CH3 domain. For example, an immunoglobulin heavy chain constant region may include an immunoglobulin hinge region, a CH2 domain, and a CH3 domain. In some embodiments, the Fc subunit described in the present disclosure is composed of a hinge-CH2-CH3 domain.
[0110] As used herein, the term "complexed with" or "complex" generally refers to the association (e.g., binding) of one member / subunit of a molecule (e.g., a protein heterodimer) with another member / subunit. For example, a first Fc subunit can complex with a second subunit to form a dimer.
[0111] As used herein, the term "binding specificity" generally refers to the ability to specifically bind to a given target (e.g., immunoreact with a given target) without binding or substantially binding to non-targets. The targeting moieties of the present disclosure can be monospecific and contain one or more binding sites that specifically bind to a target, or can be multispecific (e.g., bispecific or trispecific) and contain two or more binding sites that specifically bind to the same or different targets.
[0112] As used herein, the term "associated with" or "caused to be associated with" generally refers to the physical association or contact of one entity with another entity. For example, a first monomer member of a protein heterodimer can be "associated" with a second monomer member, either covalently or non-covalently. In some embodiments, the first monomer member of a protein heterodimer associates with the second monomer member via an interface formed by amino acid residues from each of the first and second monomer members (i.e., interface residues).
[0113] As used herein, the term "modification" generally refers to any manipulation of the peptide backbone (e.g., amino acid sequence) or any post-translational modification (e.g., glycosylation) of a polypeptide. For example, the modification is relative to the sequence of the corresponding wild-type polypeptide. The modification can be a substitution, addition, and / or deletion of one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more).
[0114] As used herein, the term "knob-and-hole modification" generally refers to the introduction of a modification at a polypeptide interface to form a protrusion (knob modification) and the introduction of a modification at the corresponding position of another polypeptide to form a cavity (hole modification), the size of the protrusion being the same or similar to the size of the cavity. For example, the knob-and-hole modification allows the formation of heterodimers while inhibiting the formation of homodimers. See references U.S. Patent No. 5,731,168; U.S. Patent No. 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Accordingly, as used herein, the term "knob modification" generally refers to a modification at a polypeptide interface in which an amino acid with a smaller side chain (e.g., alanine or threonine) is replaced with an amino acid with a larger side chain (e.g., tyrosine or tryptophan) to form a protrusion. As used herein, the term "hole modification" generally refers to a modification at the corresponding position of another polypeptide, which replaces an amino acid with a larger side chain (e.g., tyrosine or tryptophan) with an amino acid with a smaller side chain (e.g., alanine or threonine) to form a cavity. Knob modifications and hole modifications can be performed by altering the nucleotides encoding the polypeptide (e.g., by site-specific mutagenesis) or by peptide synthesis. In a specific embodiment, the knob modification comprises amino acid substitutions Y349C and T366W in one of the two subunits of the Fc region, and the hole modification comprises amino acid substitutions D356C, T366S, L368A, and Y407V in the other of the two subunits of the Fc region.
[0115] As used herein, the term "HEK293 cells" generally refers to a clonal isolate derived from transformed human embryonic kidney (HEK) cells. The HEK293 cell line is a variant of the 293 cell line that exhibits better adherence in monolayer culture and is readily used for plaque assays and other anchorage-dependent applications. It has been adapted for suspension culture in serum-free medium (293SFM II).
[0116] As used herein, the term "CHO cells" generally refers to Chinese hamster ovary cells, which are non-secreting immortalized fibroblasts. CHO cells rarely secrete CHO endogenous proteins, thus facilitating the isolation and purification of target proteins.
[0117] As used herein, the term "CHO-1 cells" generally refers to a fibroblast-like cell line derived from monkey kidney tissue. COS cells are derived by immortalizing CV-1 cells with a form of the SV40 virus that produces a large T antigen but is defective in genome replication. A commonly used form of the COS cell line is COS-1.
[0118] As used herein, the term "NS0 cells" generally refers to a model cell line derived from a non-secretory mouse myeloma. The cell line is a cholesterol-dependent cell line derived from a branch of NSI / 1.
[0119] As used herein, the term "fusion protein" generally refers to a polypeptide that comprises, or alternatively consists of, an amino acid sequence that is one polypeptide fused directly or indirectly (e.g., via a linker) to the amino acid sequence of a heterologous polypeptide (i.e., a polypeptide that is unrelated to the previous polypeptide or a domain thereof).
[0120] As used herein, the term "C-terminus" generally refers to the carboxyl terminus of a polypeptide.
[0121] As used herein, the term "N-terminus" generally refers to the amino terminus of a polypeptide.
[0122] As used herein, the term "immunoglobulin" generally refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. Identified immunoglobulin genes include kappa, lambda, alpha, gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon, and mu constant region genes, as well as numerous immunoglobulin variable region genes. One form of immunoglobulin constitutes the basic structural unit of an antibody. This form is a tetramer and consists of two identical immunoglobulin chain pairs, each pair having a light chain and a heavy chain. In each pair, the light chain variable region and the heavy chain variable region are jointly responsible for binding to the antigen, while the constant region is responsible for the antibody effector function. In addition to antibodies, immunoglobulins can exist in various other forms including, for example, Fv, Fab, Fab', and (Fab')2.
[0123] As used herein, the term "fused in frame" or "inframe fused" generally refers to joining two or more open reading frames (orfs) to form a continuous longer orf in a manner that maintains the correct reading frame of the original orfs.
[0124] As used herein, the term "linker" generally refers to a synthetic amino acid sequence that connects or links two polypeptide sequences (e.g., links two polypeptide domains). The linker can connect the two amino acid sequences via a peptide bond. In some embodiments, the linker of the present disclosure connects the immunomodulatory factor to the second Fc region in the linear sequence.
[0125] As used herein, the term "located at the N-terminus of..." generally refers to being located at the N-terminal position of another molecule (eg, another polypeptide). For example, according to the present disclosure, two or more immunomodulatory factors can be located at the N-terminus of the second Fc region.
[0126] As used herein, the term "amino acid substitution" generally refers to the replacement of an amino acid at a specific position in a polypeptide with another amino acid.
[0127] As used herein, the term "KABAT numbered EU index" generally refers to the index corresponding to the EU numbering of amino acid sequences according to KABAT et al. (1971) Ann. NY Acad, Sci. 190:382-391 and Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., U.S. Department of Health and Human Services, NIH Publication No. 91-3242.
[0128] As used herein, the term "isolated polynucleotide" generally refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides or their analogs, separated from their natural environment or artificially synthesized.
[0129] As used herein, the term "protein mixture" generally refers to a mixture of two or more proteins.
[0130] As used herein, the term "homodimer" generally refers to a molecule formed by two identical monomers (e.g., two identical members or subunits). The two monomers can aggregate, complex, or associate with each other via covalent and / or non-covalent interactions. For example, the two monomers of a protein homodimer can associate with each other via interactions between interfacial amino acid residues from each of the two monomers.
[0131] As used herein, the term "substantially free" generally means that a composition (e.g., a mixture) includes very little or almost no substance. For example, the substance is present at a percentage of, for example, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, or less than 0.01%.
[0132] As used herein, the term "pharmaceutically acceptable excipient" generally refers to any and all solvents, dispersion media, coatings, strong absorption delaying agents, and the like, compatible with pharmaceutical administration.
[0133] As used herein, the term "enrichment" generally refers to an increase in the number and / or concentration of a target component in a mixture or population.
[0134] As used herein, the term "interleukin 10" generally refers to IL-10, also known as human cytokine synthesis inhibitory factor (CSIF), which is an anti-inflammatory cytokine. Human IL-10 can be encoded by the gene IL10. The structure of the interleukin 10 can be a homodimer, and each subunit thereof is 178 amino acids in length.
[0135] As used herein, the term "asymmetric dimer" generally refers to a dimer whose structure is asymmetric. For example, an asymmetric dimer can be a molecule formed by two different monomer members. The two monomer members can aggregate, complex or associate with each other via covalent and / or non-covalent interactions. The asymmetric dimers on either side of the centerline can be different.
[0136] Protein heterodimers, protein mixtures, isolated polynucleotides, vectors and host cells
[0137] In one aspect, the present disclosure provides a protein heterodimer. The protein heterodimer may include a first monomer member and a second monomer member different from the first monomer member. The first monomer member may include a first Fc subunit. The second monomer member may include a second Fc subunit. The first monomer member may associate with the second monomer member to form a heterodimer through complexation of the first Fc subunit and the second Fc subunit.
[0138] In some embodiments, the amino acid sequence of the first monomer member is different from the amino acid sequence of the second monomer member.
[0139] The protein heterodimer may further include one or more interleukins. The one or more interleukins may be fused to the first Fc subunit and / or the second Fc subunit (e.g., in-frame fusion). For example, the one or more interleukins may be independently fused to the first Fc subunit and / or the second Fc subunit in-frame (e.g., in-frame fusion). In some embodiments, one or more interleukins are only fused to the first Fc subunit (e.g., in-frame fusion). In some embodiments, one or more interleukins are only fused to the second Fc subunit (e.g., in-frame fusion). In some embodiments, one or more interleukins are fused to the first Fc subunit and the second Fc subunit (e.g., in-frame fusion).
[0140] The one or more interleukins can be fused to the amino-terminal amino acid and / or carboxyl-terminal amino acid of the first Fc subunit and / or the second Fc subunit (e.g., fused in frame). In some embodiments, the one or more interleukins are fused to the amino-terminal amino acid of the first Fc subunit (e.g., in frame). In some embodiments, the one or more interleukins are fused only to the amino-terminal amino acid of the second Fc subunit (e.g., in frame). In some embodiments, the one or more interleukins are fused to the amino-terminal amino acid of the first Fc subunit and the amino-terminal amino acid of the second Fc subunit (e.g., in frame).
[0141] In the protein heterodimer, at least one of the one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) interleukins can be interleukin 10.
[0142] The one or more interleukins can be fused directly or indirectly with the first Fc subunit and / or the second Fc subunit (e.g., in frame). For example, the one or more interleukins can be fused (e.g., in frame) with the first Fc subunit and / or the second Fc subunit via a joint (such as a peptide joint). The joint can be, for example, a synthetic amino acid sequence that connects or links two polypeptide sequences via a peptide bond. In some embodiments, the joint is a peptide comprising, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more amino acids. For example, the joint can include 1 to 10 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids), 1 to 15 amino acids (e.g., 1 to 11, 12, 13, 14, 15 amino acids), 1 to 20 amino acids, 1 to 30 amino acids or more amino acids. In some embodiments, the linker comprises that shown in SEQ ID NO:37.
[0143] In some embodiments, the protein heterodimer includes two or more interleukins. The two or more interleukins can be the same or different. In some embodiments, the two or more interleukins are the same. In some embodiments, the two or more interleukins are interleukin 10.
[0144] The two or more interleukins can form one or more interleukin dimers, each interleukin dimer including two interleukins fused to each other (e.g., in a frame). Each interleukin dimer can include two identical or two different interleukins. The interleukins can be fused together (e.g., in a frame) directly or indirectly. In some embodiments, one or more interleukin dimers include at least one interleukin 10 dimer, and the interleukin 10 dimer includes two interleukins 10.
[0145] In some embodiments, the joint comprises 1 to 10 amino acids (e.g., 1 to 15 amino acids) or 1 to 15 amino acids (e.g., 1 to 11, 12, 13, 14, 15 amino acids), 1 to 20 amino acids, 1 to 30 amino acids, or more amino acids. In some embodiments, the joint comprises SEQ ID NO:37. In some embodiments, the linker is resistant or substantially resistant to proteolysis.
[0146] In some cases, two or more interleukins can be included in a protein heterodimer. The two or more interleukins can form two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) interleukin dimers. For example, the two or more interleukin dimers can include at least one interleukin 10 dimer, and the interleukin 10 dimer includes two interleukins 10. In some embodiments, the protein heterodimer includes two or more interleukin 10 dimers.
[0147] The two or more interleukins (e.g., interleukin dimer) that are fused can be further fused to the amino-terminal amino acid and / or carboxyl-terminal amino acid of the first Fc subunit and / or the second Fc subunit (e.g., in frame). In some embodiments, the two or more interleukins (e.g., interleukin dimer) that are fused can be further fused to the amino-terminal amino acid of the first Fc subunit and / or the second Fc subunit. In some embodiments, the two or more interleukins (e.g., interleukin dimer) that are fused can be further fused only to the amino-terminal amino acid of the first Fc subunit. In some embodiments, the two or more interleukins (e.g., interleukin dimer) that are fused can be further fused only to the amino-terminal amino acid of the second Fc subunit. In some embodiments, the two or more interleukins (e.g., interleukin dimer) that are fused can be further fused to the amino-terminal amino acid of the first Fc subunit and the amino-terminal amino acid of the second Fc subunit.
[0148] In some embodiments, the two or more interleukins (e.g., interleukin dimer) that are fused are further fused to the carboxyl terminal amino acid of the first Fc subunit and / or the second Fc subunit. In some embodiments, the two or more interleukins (e.g., interleukin dimer) that are fused can further be fused only to the carboxyl terminal amino acid of the first Fc subunit. In some embodiments, the two or more interleukins (e.g., interleukin dimer) that are fused can further be fused only to the carboxyl terminal amino acid of the second Fc subunit. In some embodiments, the two or more interleukins (e.g., interleukin dimer) that are fused can further be fused to the carboxyl terminal amino acid of the first Fc subunit and the carboxyl terminal amino acid of the second Fc subunit.
[0149] When there are two or more interleukin dimers, each interleukin dimer can be independently fused to the amino-terminal amino acid and / or carboxyl-terminal amino acid of the first Fc subunit and / or the second Fc subunit. For example, two or more fusion interleukins (e.g., interleukin 10) can be further fused to the first Fc subunit (e.g., with its amino-terminal amino acid) (e.g., within a frame), and two or more fusion interleukins (e.g., interleukin 10) can be further fused to the second Fc subunit (e.g., with its amino-terminal amino acid) (e.g., within a frame). For another example, two or more fusion interleukins (e.g., interleukin 10) can be further fused to the first Fc subunit (e.g., with its carboxyl-terminal amino acid) (e.g., within a frame), and two or more fusion interleukins (e.g., interleukin 10) can be further fused to the second Fc subunit (e.g., with its carboxyl-terminal amino acid) (e.g., within a frame).
[0150] The two or more interleukins (e.g., interleukin dimers) of fusion can be fused directly or indirectly with the first Fc subunit and / or the second Fc subunit. For example, the two or more interleukins (e.g., interleukin dimers) of fusion can be fused with the first Fc subunit and / or the second Fc subunit via a joint (such as a peptide joint). The joint can be, for example, a synthetic amino acid sequence that connects or links two polypeptide sequences via a peptide bond. In some embodiments, the joint is a peptide comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more amino acids. For example, the linker can include 1 to 10 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids), 1 to 15 amino acids (e.g., 1 to 11, 12, 13, 14, 15 amino acids), 1 to 20 amino acids, 1 to 30 amino acids or more amino acids. In some embodiments, the linker includes that shown in SEQ ID NO: 37. In some embodiments, the linker is resistant to proteolysis or substantially resistant to proteolysis.
[0151] In some embodiments, at least one of the one or more interleukins is fused to a second Fc subunit (e.g., in frame). For example, at least one of the one or more interleukins can be fused to the amino-terminal amino acid of the second Fc subunit.
[0152] In some embodiments, in the second monomer member, at least two of the one or more interleukins are fused to each other (e.g., in frame) to form an interleukin dimer, which is further fused to the amino-terminal amino acid of the second Fc subunit (in frame).
[0153] In some embodiments, the first monomer member does not include any interleukins.
[0154] In some embodiments, the first monomer member consists of the first Fc subunit.
[0155] In some embodiments, at least one of the one or more interleukins is fused (eg, in frame) to the first Fc subunit.
[0156] In some embodiments, at least one of the one or more interleukins is fused (eg, in frame) to the amino-terminal amino acid of the first Fc subunit.
[0157] In some embodiments, in the first monomer member, at least two of the one or more interleukins are fused to each other (e.g., in frame) to form an interleukin dimer, which is further fused to the amino-terminal amino acid of the first Fc subunit (e.g., in frame).
[0158] In some embodiments, the second monomer member does not include any interleukins.
[0159] In some embodiments, the second monomer member consists of a second Fc subunit.
[0160] In some embodiments, the first monomer member does not include any interleukin, or the first monomer member is composed of a first Fc subunit, and at least one of the one or more interleukins is fused to a second Fc subunit (e.g., within a frame). In some cases, in the second monomer member, at least two of the one or more interleukins are fused to each other (e.g., within a frame) to form an interleukin dimer, which is further fused to the amino-terminal amino acid of the second Fc subunit (within a frame).
[0161] In some embodiments, the second monomer member does not include any interleukin, or the second monomer member is composed of a second Fc subunit, and at least one of the one or more interleukins is fused to the first Fc subunit (e.g., within the frame). In some cases, in the second monomer member, at least two of the one or more interleukins are fused to each other (e.g., within the frame) to form an interleukin dimer, which is further fused to the amino-terminal amino acid of the first Fc subunit (within the frame).
[0162] In some embodiments, the first monomer member comprises one or more interleukins fused to a first Fc subunit and the second monomer member comprises one or more interleukins fused to a second Fc subunit.
[0163] In some embodiments, the first monomer member includes one or more interleukin dimers fused to a first Fc subunit, and the second monomer member includes one or more interleukin dimers fused to a second Fc subunit. Each interleukin dimer can include two identical interleukins fused (e.g., in frame) to each other directly or indirectly (e.g., via a linker, such as a peptide linker).
[0164] The protein heterodimers of the present application do not include any antibody heavy chain variable region or any antibody light chain variable region that exhibits binding specificity to a tumor antigen. In some embodiments, the protein heterodimers of the present application do not include any antibody or any portion thereof (e.g., antigen binding fragment) that exhibits binding specificity to a tumor antigen.
[0165] In some embodiments, the protein heterodimers of the present application do not include any antibody heavy chain variable region or any antibody light chain variable region.
[0166] In some embodiments, the protein heterodimers of the present application do not include any antibodies or antigen-binding fragments thereof.
[0167] In some embodiments, the protein heterodimers of the present application do not include any targeting moiety that exhibits binding specificity to any tumor antigen. For example, in some cases, the protein heterodimers of the present application do not include any antibody or antigen-binding fragment thereof that can specifically bind to a tumor antigen.
[0168] In some embodiments, the first Fc subunit and / or the second Fc subunit are independently derived from an IgG molecule. The IgG can be selected from the group consisting of IgG1, IgG2, IgG3, and IgG4. For example, the IgG can be human IgG1.
[0169] In some embodiments, the first Fc subunit is different from the second Fc subunit, and the first and / or second Fc subunit comprises a modification that promotes heterodimerization between the first Fc subunit and the second Fc subunit.
[0170] In some embodiments, the first Fc subunit can include a first modification and the second Fc subunit can include a second modification. In some embodiments, the first modification is different from the second modification.
[0171] In some embodiments, the first modification comprises an amino acid substitution at position T366, and an amino acid substitution at one or more positions selected from the group consisting of: Y349, F405, K409, D399, K360, Q347, K392, and S354, wherein the amino acid positions are determined according to the EU index of KABAT numbering. For example, the first modification comprises an amino acid substitution selected from the group consisting of: Y349C, Y349D, D399S, F405K, K360E, K409A, K409E, Q347E, Q347R, S354D, K392D, and T366W.
[0172] In some embodiments, the first modification comprises 2 to 5 amino acid substitutions.
[0173] In some embodiments, the first modification comprises an amino acid substitution at a group of positions selected from any one of the following groups: 1) Y349 and T366; 2) Y349, T366, and F405; 3) Y349, T366, and K409; 4) Y349, T366, F405, K360, and Q347; 5) Y349, T366, F405, and Q347; 6) Y349, T366, K409, K360, and Q347; 7) Y349, T366, K409 and Q347; 8) T366, K409 and K392; 9) T366 and K409; 10) T366, K409, Y349 and S354; 11) T366 and F405; 12) T366, F405 and D399; and 13) T366, F405, Y349 and S354; wherein the positions of the amino acids are determined according to the EU index with KABAT numbering.
[0174] In some embodiments, the first modification comprises a set of amino acid substitutions selected from any one of the following groups: 1) Y349C and T366W; 2) Y349C, T366W, and F405K; 3) Y349C, T366W, and K409E; 4) Y349C, T366W, and K409A; 5) Y349C, T366W, F405K, K360E, and Q347E; 6) Y349C, T366W, F405K, and Q347R; 7) Y349C, T366W, K409A, K360E, and Q347E; 8) Y349C, T366W, K409A and Q347R; 9) T366W, K409A and K392D; 10) T366W and K409A; 11) T366W, K409A and Y349D; 12) T366W, K409A, Y349D and S354D; 13) T366W and F405K; 14) T366W, F405K and D399S; 15) T366W, F405K and Y349D; and 16) T366W, F405K, Y349D and S354D; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0175] In some embodiments, the second modification comprises an amino acid substitution at positions T366, L368, and Y407, and an amino acid substitution at one or more positions selected from the group consisting of D356, D399, E357, F405, K360, K392, K409, and Q347, wherein the positions of amino acids are determined according to the EU index with KABAT numbering.
[0176] In some embodiments, the second modification comprises an amino acid substitution selected from the group consisting of D356C, D399S, E357A, F405K, K360E, K392D, K409A, L368A, L368G, Q347E, Q347R, T366S, Y407A, and Y407V.
[0177] In some embodiments, the second modification comprises amino acid substitutions at positions 4 to 6.
[0178] In some embodiments, the second modification comprises an amino acid substitution at a group of positions selected from any one of the following groups: 1) D356, T366, L368, Y407, and F405; 2) D356, T366, L368, and Y407; 3) D356, T366, L368, Y407, and Q347; 4) D356, T366, L368, Y407, K360, and Q347; 5) D356, T366, L368, Y407, F405, and Q347; 6) D356, T366, L368, Y407 , F405, K360 and Q347; 7) T366, L368, Y407, D399 and F405; 8) T366, L368, Y407 and F405; 9) T366, L368, Y407, F405 and E357; 10) T366, L368, Y407 and K409; 11) T366, L368, Y407, K409 and K392; and 12) T366, L368, Y407, K409 and E357; wherein the positions of amino acids are determined according to the EU index using KABAT numbering.
[0179] In some embodiments, the second modification comprises an amino acid substitution at a group of positions selected from any one of the following groups: 1) D356C, T366S, L368A, Y407V, and F405K; 2) D356C, T366S, L368A, and Y407V; 3) D356C, T366S, L368A, Y407V, and Q347R; 4) D356C, T366S, L368A, Y407V, K360E, and Q347E; 5) D356C, T366S, L368A, Y407V, F405K, and Q347R; 6) D356C, T366S, L368A, Y407V, F405K, K360E, and Q347R. 347E; 7) T366S, L368A, Y407V, D399S and F405K; 8) T366S, L368G, Y407A and F405K; 9) T366S, L368A, Y407V, F405K and E357A; 10) T366S, L368A, Y407V and K409A; 11) T366S, L368A, Y407V, K409A and K392D; 12) T366S, L368G, Y407A and K409A; 13) T366S, L368A, Y407V, K409A and E357A; wherein the positions of amino acids are determined according to the EU index using KABAT numbering.
[0180] In some embodiments, the first Fc subunit comprises a first modification, the second Fc subunit comprises a second modification, and the first modification and the second modification comprise amino acid substitutions at a group of positions selected from any one of the following groups: 1) first modification: Y349 and T366; and second modification: D356, T366, L368, Y407, and F405; 2) first modification: Y349, T366, and F405; and second modification: D356, T366, L368, and Y407; 3) first modification: Y349, T366, and K409; and second modification: D356, T366, L368, Y407, and F405; 4) first modification: Y349, T366, and K409; and second modification: D356, T366, L368, Y407, and F405. 66, F405, K360 and Q347; and second modification: D356, T366, L368, Y407 and Q347; 5) first modification: Y349, T366, F405 and Q347; and second modification: D356, T366, L368, Y407, K360 and Q347; 6) first modification: Y349, T366, K409, K360 and Q347; and second modification: D356, T366, L368, Y407, F405 and Q347; 7) first modification: Y349, T366, K409 and Q347; and second modification: D356, T366, L368, Y407 , F405, K360 and Q347; 8) first modification: T366, K409 and K392; and second modification: T366, L368, Y407, D399 and F405; 9) first modification: T366 and K409; and second modification: T366, L368, Y407 and F405; 10) first modification: T366, K409 and Y349; and second modification: T366, L368, Y407, F405 and E357; 11) first modification: T366, K409, Y349 and S354; and second modification: T366, L368, Y407, F405 and E357; 12) first modification : T366 and F405; and the second modification: T366, L368, Y407 and K409; 13) the first modification: T366, F405 and D399; and the second modification: T366, L368, Y407, K409 and K392; 14) the first modification: T366, F405 and Y349; and the second modification: T366, L368, Y407, K409 and E357; 15) the first modification: T366, F405, Y349 and S354; and the second modification: T366, L368, Y407, K409 and E357; wherein the positions of the amino acids are determined according to the EU index of KABAT numbering.
[0181] In some embodiments, the first Fc subunit comprises a first modification and the second Fc subunit comprises a second modification, wherein the first modification and the second modification comprise a set of amino acid substitutions selected from any one of the following groups: 1) first modification: Y349C and T366W; and second modification: D356C, T366S, L368A, Y407V, and F405K; 2) first modification: Y349C, T366W, and F405K; and second modification: D356C, T366S, L368A, and Y407V; 3) first modification: Y349C, T366W, and K409E; and second modification: D356C, T366S, L368A, Y407V, and F405K; 4) first modification: Y349C, T366W, and K409A; and second modification: D356C, T366S, L368A, Y407V, and F405K; 5) first modification: Y349C, T366W, F405K, K360E, and Q347E; and second modification: D356C, T366S, L368A, Y407V, and Q347R; 6) first modification: Y349C, T366W, F405K, and Q347R; and second modification: D356C, T366S, L368A, Y407V, K360E, and Q347E; 7) first modification: Y349C, T366W, K409A, K360E, and Q347E; and second modification: D 356C, T366S, L368A, Y407V, F405K and Q347R; 8) first modification: Y349C, T366W, K409A and Q347R; and second modification: D356C, T366S, L368A, Y407V, F405K, K360E and Q347E; 9) first modification: T366W, K409A and K392D; and second modification: T366S, L368A, Y407V, D399S and F405K; 10) first modification: T366W and K409A; and second modification: T366S, L368G, Y407A and F405K; 11) first modification: T366W, K409 A and Y349D; and second modification: T366S, L368A, Y407V, F405K and E357A; 12) first modification: T366W, K409A, Y349D and S354D; and second modification: T366S, L368A, Y407V, F405K and E357A; 13) first modification: T366W and F405K; and second modification: T366S, L368A, Y407V and K409A; 14) first modification: T366W, F405K and D399S; and second modification: T366S, L368A, Y407V, K409A and K392D; 15) first modification: T366W and F405K;and a second modification: T366S, L368G, Y407A, and K409A; 16) a first modification: T366W, F405K, and Y349D; and a second modification: T366S, L368A, Y407V, K409A, and E357A; 17) a first modification: T366W, F405K, Y349D, and S354D; and a second modification: T366S, L368A, Y407V, K409A, and E357A; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0182] In some embodiments, the first Fc subunit comprises a first modification and the second Fc subunit comprises a second modification, the first modification comprises amino acid substitutions T366W and K409A, and the second modification comprises amino acid substitutions T366S, L368G, Y407A, and F405K, wherein the positions of amino acids are determined according to the EU index with KABAT numbering.
[0183] In some embodiments, the first and second Fc subunits include modifications that promote heterodimerization between the first Fc subunit and the second Fc subunit, such as a knob-to-hole modification. For example, the first Fc subunit may include a knob modification, and the second Fc subunit may include a hole modification. For another example, the first Fc subunit may include a hole modification, and the second Fc subunit may include a knob modification.
[0184] The knob modification may include amino acid substitutions Y349C and T366W, and the hole modification may include amino acid substitutions D356C, T366S, L368A, and Y407V, wherein the positions of the amino acids are determined according to the Eu index of Kabat numbering.
[0185] In some embodiments, the amino acid sequence of the first Fc subunit is selected from the group consisting of SEQ ID NO: 1, 3, 5, 6, 7, 9, 11, 13, 15, 17, 19, 21, 22, 24, 27, 29, and 30.
[0186] In some embodiments, the amino acid sequence of the interleukin included in the protein heterodimer is selected from the group consisting of SEQ ID NOs: 49 and 51.
[0187] In some embodiments, the amino acid sequence of the second Fc subunit is selected from the group consisting of SEQ ID NO: 2, 4, 8, 10, 12, 14, 16, 18, 20, 23, 25, 26, 28, and 30.
[0188] In one aspect, the present disclosure provides one or more isolated nucleic acids encoding a protein heterodimer according to the present disclosure. In some embodiments, the isolated nucleic acid encodes a monomeric member (e.g., a first monomeric member or a second monomeric member) or a fragment of a protein heterodimer according to the present disclosure.
[0189] Nucleic acids can be synthesized using recombinant techniques known in the art. For example, nucleic acids can be synthesized using an automated DNA synthesizer.
[0190] Standard recombinant DNA and molecular cloning techniques include those described by Sambrook, J., Fritsch, E.F. and Maniatis, T. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, (1989) (Maniatis) and T.J. Silhavy, M.L. Bennan, and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1984) and Ausubel, F.M. et al., Current Protocols in Molecular Biology, Green Publishing Associates and Wiley & Sons, Inc. (1987). Briefly, the disclosed nucleic acids can be prepared from genomic DNA fragments, cDNA, and RNA, which can be extracted directly from cells or produced recombinantly by various amplification techniques including, but not limited to, PCR and RT-PCR.
[0191] Direct chemical synthesis of nucleic acids typically involves the sequential addition of 3'-blocked and 5'-blocked nucleotide monomers to the 5' hydroxyl terminus of a growing nucleotide polymer chain, wherein each addition is achieved by nucleophilic attack on the 5' hydroxyl terminus of the growing chain at the 3' position of the added monomer, the added monomer typically being a phosphorus derivative such as a phosphotriester, phosphoramidite, etc. See, for example, Matteuci et al., Tet. Lett. 521:719 (1980); U.S. Pat. No. 4,500,707 to Caruthers et al.; and U.S. Pat. Nos. 5,436,327 and 5,700,637 to Southern et al.
[0192] In one aspect, the present disclosure provides one or more vectors comprising one or more isolated nucleic acids according to the present disclosure.
[0193] The vector can be any linear nucleic acid, plasmid, phagemid, cosmid, RNA vector, viral vector, etc. Non-limiting examples of viral vectors can include retroviruses, adenoviruses, and adeno-associated viruses. In some embodiments, the vector is an expression vector, such as a phage display vector.
[0194] An expression vector may be adapted for use with a particular type of host cell but not with another. For example, an expression vector may be introduced into a host organism and then monitored for activity and expression of any gene / polynucleotide contained within the vector.
[0195] The expression vector may also contain one or more selectable marker genes that, when expressed, confer one or more phenotypic traits that can be used to select or otherwise identify host cells carrying the expression vector. Non-limiting examples of selectable markers suitable for eukaryotic cells include dihydrofolate reductase and neomycin resistance.
[0196] The disclosed vectors can be stably or transiently introduced into host cells by a variety of established techniques. For example, one method involves calcium chloride treatment, wherein the expression vector is introduced via calcium precipitation. Other salts, such as calcium phosphate, can also be used following similar procedures. In addition, electroporation (i.e., the application of an electric current to increase the permeability of the cell to the nucleic acid) can be used. Other examples of transformation methods include microinjection, DEAE dextran-mediated transformation, and heat shock in the presence of lithium acetate. Lipid complexes, liposomes, and dendrimers can also be used to transfect host cells.
[0197] When introducing heterologous sequences into host cells, various methods can be practiced to identify host cells into which the disclosed vectors have been introduced. One exemplary selection method involves subculturing individual cells to form individual colonies, followed by testing for expression of the desired protein product. Another method involves selecting host cells containing the heterologous sequence based on a phenotypic trait conferred by expression of a selectable marker gene contained within the expression vector.
[0198] For example, the introduction of various heterologous sequences disclosed herein into host cells can be confirmed by methods such as PCR, Southern blotting or Northern blot hybridization. For example, nucleic acids can be prepared from the resulting host cells, and the specific sequence of interest can be amplified by PCR using primers specific for the sequence of interest. The amplified product is subjected to agarose gel electrophoresis, polyacrylamide gel electrophoresis or capillary electrophoresis, followed by staining with ethidium bromide, SYBR Green solution or the like, or by UV detection to detect the DNA. Alternatively, a nucleic acid probe specific for the sequence of interest can be used in a hybridization reaction. The expression of a specific gene sequence can be determined by detecting the corresponding mRNA by reverse transcription combined with PCR, Northern blot hybridization, or by immunoassay using antibodies that react with the encoded gene product. Exemplary immunoassays include, but are not limited to, ELISA, radioimmunoassays and sandwich immunoassays.
[0199] In addition, the introduction of various heterologous sequences of the present disclosure into host cells can be determined by the enzymatic activity of an enzyme (e.g., an enzyme marker) encoded by the heterologous sequence. The enzyme can be analyzed by various methods known in the art. In general, enzymatic activity can be confirmed by the formation of a product or the conversion of a substrate in an enzymatic reaction under study. The reaction can occur in vitro or in vivo.
[0200] In one aspect, the present disclosure provides an isolated host cell comprising one or more isolated nucleic acids or one or more vectors according to the present disclosure.
[0201] The host cell can be a eukaryotic cell or a prokaryotic cell. Suitable host cells can be transformed or transfected with polynucleotides of the present disclosure or carriers, and used for expression and / or secretion of heterodimeric proteins and / or protein mixtures. For example, the cell can be an Escherichia coli cell, other bacterial host cells, yeast cells or various higher eukaryotic cells (for example immortal hybridoma cells, NSO myeloma cells, HEK293 cells, Chinese hamster ovary cells, HeLa cells, COS cells etc.). In some embodiments, the nucleic acid encoding the protein heterodimer (for example heterodimeric protein) is operably linked to an expression control sequence suitable for expression in a specific host cell.
[0202] In one aspect, the present disclosure provides a protein mixture. The protein mixture may include: 1) a protein heterodimer according to the present disclosure; 2) a first homodimer formed by two identical copies of a first monomer member of the protein heterodimer according to the present disclosure; and 3) a second homodimer formed by two identical copies of a second monomer member of the protein heterodimer according to the present disclosure. The percentage of the protein heterodimer in the protein mixture may be at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%.
[0203] In the protein mixture, the percentage of the second homodimer can be less than the percentage of the first homodimer. For example, the percentage of the second homodimer can be at most about 10%, at most about 9%, at most about 8%, at most about 7%, at most about 6%, at most about 5%, at most about 4%, at most about 3%, at most about 2%, at most about 1% or at most about 0.5%. For example, the protein mixture can essentially not include the second homodimer.
[0204] The protein mixture can be produced directly by the host cells of the present disclosure, e.g., without the need to enrich / purify protein heterodimers and / or remove the first or second homodimers.
[0205] Pharmaceutical composition
[0206] In one aspect, the present disclosure provides a pharmaceutical composition comprising a protein heterodimer according to the present disclosure, or a protein mixture according to the present disclosure, and optionally a pharmaceutically acceptable excipient.
[0207] Examples of pharmaceutically acceptable excipients include, but are not limited to, inert solid diluents and fillers, diluents, sterile aqueous solutions and various organic solvents, penetration enhancers, solubilizers, and adjuvants.
[0208] In some embodiments, the protein heterodimer is formulated for oral administration, intravenous administration, intramuscular administration, in situ administration at a tumor site, inhalation, rectal administration, vaginal administration, transdermal administration, or administration via a subcutaneous depot.
[0209] The pharmaceutical composition can be used to inhibit tumor growth. For example, the pharmaceutical composition can inhibit or delay the development or progression of a disease, can reduce tumor size (and even substantially eliminate a tumor), and can alleviate and / or stabilize the disease condition.
[0210] Non-limiting exemplary pharmaceutical compositions and methods for their preparation are described below.
[0211] The pharmaceutical composition of the present disclosure can be, for example, in a form suitable for oral administration, such as tablets, capsules, pills, powders, sustained-release preparations, solutions, suspensions; in a form suitable for parenteral injection, such as sterile solutions, suspensions or emulsions; in a form suitable for topical administration, such as ointments or creams; or in a form suitable for rectal administration, such as suppositories. The pharmaceutical composition can be in a unit dosage form suitable for single administration of an exact dose. The pharmaceutical composition can further include a protein heterodimer (such as a heterodimeric protein) or a protein mixture according to the present disclosure as an active ingredient and can include conventional pharmaceutical carriers or excipients. Further, the pharmaceutical composition can include other medicines or pharmaceutical agents, carriers, adjuvants, etc.
[0212] Exemplary parenteral administration forms include, but are not limited to, solutions or suspensions of active protein heterodimers (e.g., heterodimeric proteins) dissolved in sterile aqueous solution (e.g., aqueous propylene glycol or glucose solution). Where necessary, these dosage forms can be appropriately buffered with salts such as histidine and / or phosphate.
[0213] In some embodiments, the present disclosure provides a pharmaceutical composition for injection, which contains the protein heterodimer (heterodimeric protein) or protein mixture of the present disclosure and a pharmaceutical excipient suitable for injection.
[0214] Forms in which the pharmaceutical compositions of the present disclosure may be incorporated for administration by injection include aqueous or oily suspensions or emulsions containing sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, glucose, or sterile aqueous solutions and similar pharmaceutical vehicles.
[0215] In some embodiments, the present disclosure provides a pharmaceutical composition for oral administration, which contains the protein heterodimer (heterodimeric protein) or protein mixture of the present disclosure and a pharmaceutical excipient suitable for oral administration.
[0216] In some embodiments, the present disclosure provides a solid pharmaceutical composition for oral administration, which contains: (i) a certain amount of a protein heterodimer (e.g., a heterodimeric protein) or a protein mixture of the present disclosure; optionally (ii) a certain amount of a second agent; and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further contains: (iv) a certain amount of a third agent. In some embodiments, the amount of the protein heterodimer or protein mixture, the second agent, and the optional third agent is an amount that is effective for treating the condition of the individual, either alone or in combination.
[0217] In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral administration. The pharmaceutical compositions of the present disclosure suitable for oral administration may be in the form of discrete dosage forms such as capsules, cachets or tablets, or liquids or sprays containing a predetermined amount of the active ingredient (e.g., powder), or in the form of granules, solutions or suspensions dissolved in aqueous or non-aqueous solutions, oil-in-water emulsions or water-in-oil liquid emulsions. These dosage forms may be prepared by any pharmaceutical method, but all methods generally include the step of associating the active ingredient with a carrier comprising one or more other ingredients. In general, the composition is prepared by uniformly and intimately admixing the active ingredient with a liquid carrier or a finely divided solid carrier or both carriers, and then, if necessary, shaping the product into the desired form.
[0218] The present disclosure further encompasses anhydrous pharmaceutical compositions and dosage forms comprising active ingredients (e.g., protein heterodimers or heterodimeric proteins of the present disclosure), as water can promote degradation of certain polypeptides. For example, in the pharmaceutical field, water can be added (e.g., 5%) as a means of simulating long-term storage in order to determine properties such as shelf life or stability of a formulation over time. The anhydrous pharmaceutical compositions and dosage forms of the present disclosure can be prepared using anhydrous or low-moisture ingredients and low-moisture or low-humidity conditions.
[0219] Protein heterodimers (e.g., heterodimeric proteins) or protein mixtures disclosed herein can be combined with pharmaceutical carriers in the form of close admixtures according to conventional pharmaceutical compounding techniques. Carriers can take various forms, depending on the form of formulation required for administration. In some embodiments where lactose is not used, when preparing a composition for oral dosage form, any conventional pharmaceutical medium can be used as a carrier, such as water, ethylene glycol, oil, alcohol, fragrance, preservative, colorant, etc., for oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starch, sugar, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrants can be used. Where necessary, tablets can be coated by standard aqueous or non-aqueous techniques.
[0220] When aqueous suspensions and / or elixirs are required for oral administration, the active ingredient therein may be combined with various sweetening or flavoring agents, coloring or dyes and, where necessary, emulsifying and / or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, and various combinations thereof.
[0221] The pharmaceutical composition of the present disclosure may include a therapeutically effective amount of an active agent (e.g., a protein heterodimer or protein mixture of the present disclosure). A therapeutically effective amount is the amount of the pharmaceutical composition of the present disclosure that can prevent and / or cure (at least in part) the subject suffering from or at risk of suffering from a condition or illness (e.g., cancer) and / or any complication thereof. The specific amount / concentration of the active agent contained can vary according to the method of administration and the needs of the patient, and can be determined based on, for example, volume, viscosity, and / or patient weight. For example, a suitable dosage can be from about 0.1 mg / kg / day or 1 mg / kg / day to about 50 mg / kg / day; sometimes, the dosage can be higher. It should be understood that these specific dosages can be suitably adjusted by those skilled in the art (e.g., a doctor or pharmacist) based on the circumstances of a particular patient, preparation, and / or disease.
[0222] Medical uses and treatments
[0223] In one aspect, the present disclosure provides a use of a protein heterodimer according to the present disclosure or a protein mixture according to the present disclosure for preparing a medicament and / or a kit for inhibiting tumor or tumor cell growth. In some embodiments, the medicament and / or kit is used to specifically and / or preferentially inhibit the growth or differentiation of target cells (e.g., cancer cells) or kill target cells (e.g., cancer cells).
[0224] In one aspect, the present disclosure provides a use of a protein heterodimer according to the present disclosure or a protein mixture according to the present disclosure for the preparation of a medicament for treating cancer in a subject in need thereof.
[0225] In one aspect, the present disclosure provides a method for treating cancer in a subject in need thereof. The method may comprise administering to the subject an effective amount of a protein heterodimer according to the present disclosure or a protein mixture according to the present disclosure.
[0226] In one aspect, the present disclosure provides a method for inhibiting tumor or tumor cell growth, comprising contacting the tumor or tumor cell with an effective amount of a protein heterodimer according to the present disclosure or a protein mixture according to the present disclosure. The contact can be performed in vitro or in vivo.
[0227] In some embodiments, the contacting comprises administering a protein heterodimer (e.g., heterodimeric protein), protein mixture, pharmaceutical composition, or drug of the present disclosure systemically or topically to a subject (e.g., a mammal). In some embodiments, the contacting comprises administering a protein heterodimer (e.g., heterodimeric protein), protein mixture, pharmaceutical composition, or drug of the present disclosure directly to a tumor site. In some embodiments, the administration is performed by oral administration, intravenous administration, intramuscular administration, in situ administration at the tumor site, inhalation, rectal administration, vaginal administration, transdermal administration, or subcutaneous depot administration.
[0228] In some embodiments, the tumor (e.g., cancer) or tumor cell (e.g., cancer cell) is a solid tumor or is derived from a solid tumor. For example, the cancer can be selected from the group consisting of: B cell lymphoma, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, breast cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain cancer or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, melanoma, uterine or endometrial cancer, oral and pharyngeal cancer, liver cancer, kidney cancer, bile duct cancer, small intestine or appendix cancer, salivary gland cancer, thyroid cancer, adrenal cancer, osteosarcoma, chondrosarcoma, liposarcoma, testicular cancer, and malignant fibrous histiocytoma.
[0229] In some embodiments, the cancer or cancer cell is in a subject, eg, the cancer or cancer cell is in a human or non-human animal (eg, a mammal).
[0230] In some embodiments, the mammal is a human. In some embodiments, the mammal is a mouse, rat, cat, dog, rabbit, pig, sheep, horse, cow, goat, gerbil, hamster, guinea pig, monkey or any other mammal. Many of these mammals can be individuals known in the art as preclinical models of certain diseases or conditions (including solid tumors and / or other cancers) (e.g., Talmadge et al., 2007 Am. J. Pathol. ("American Journal of Pathology") 170: 793; Kerbel, 2003 Canc. Biol. Therap. ("Tumor Biotherapy") 2 (4 Suppl 1): S134; Man et al., 2007 Canc. Met. Rev. 26: 737; Cespedes et al., 2006 Clin. TransL Oncol. ("Clinical Translational Oncology") 8: 318).
[0231] Method for preparing protein heterodimers or protein mixtures
[0232] In one aspect, the present disclosure provides a method for producing a protein heterodimer according to the present disclosure or a protein mixture according to the present disclosure. The method may include (i) culturing a host cell according to the present disclosure under conditions that achieve expression of the protein heterodimer, and (ii) harvesting the expressed protein heterodimer or the protein mixture including the protein heterodimer.
[0233] In some embodiments, the method does not comprise enriching for protein heterodimers in a product expressed by a host cell according to the present disclosure.
[0234] In some embodiments, the method does not comprise removing the first or second homodimer from the protein mixture produced by the host cell according to the present disclosure.
[0235] In some embodiments, the method further comprises the step of isolating and / or purifying the protein heterodimer or protein mixture.
[0236] In some embodiments, the method further comprises transfecting / transforming the host cell with a polynucleotide / vector encoding / expressing the disclosed heterodimer, one or more members thereof, or a fragment thereof.
[0237] In some embodiments, the protein heterodimers or protein mixtures of the present disclosure are produced by expressing a vector in a cell under conditions suitable for protein expression. In some embodiments, the protein heterodimers or protein mixtures of the present disclosure are produced by single cell cloning.
[0238] Factors that may vary between conditions suitable for protein expression include, for example, incubation time, temperature, and medium, and may depend on the cell type and will be readily determined by one of ordinary skill in the art.
[0239] In some embodiments, during the process of producing the protein heterodimers or protein mixtures of the present disclosure, host cells are grown in culture or in any equipment (including fermentors) that can be used to grow cultures. The cells can be grown in a monolayer or attached to a surface. Alternatively, the host cells can be grown in suspension. The cells can be grown in serum-free medium. The culture medium can be a commercially available culture medium, such as, but not limited to, Opti-CHO (Invitrogen, catalog number #12681) supplemented with glutamine (such as 8mM L-glutamine), RPMI1640 culture medium supplemented with 10% fetal bovine serum, 10.5ng / mlmIL-3 and L-glutamine, or 5% FCS culture medium.
[0240] The present disclosure also encompasses the following embodiments:
[0241] 1. A protein heterodimer comprising a first monomer member and a second monomer member different from the first monomer member, wherein: the first monomer member comprises a first Fc subunit, the second monomer member comprises a second Fc subunit, and the first monomer member associates with the second monomer member to form the heterodimer through complexing of the first Fc subunit with the second Fc subunit; wherein the protein heterodimer further comprises one or more interleukins fused to the first Fc subunit and / or the second Fc subunit; wherein the protein heterodimer does not include any antibody heavy chain variable region or any antibody light chain variable region that exhibits binding specificity for a tumor antigen.
[0242] 2. The protein heterodimer according to embodiment 1, wherein the one or more interleukins are fused to the amino-terminal amino acid and / or carboxyl-terminal amino acid of the first Fc subunit and / or the second Fc subunit.
[0243] 3. The protein heterodimer according to any one of embodiments 1 to 2, comprising two or more interleukins.
[0244] 4. The protein heterodimer according to embodiment 3, wherein the two or more interleukins form one or more interleukin dimers, each interleukin dimer comprising two interleukins fused to each other.
[0245] 5. The protein heterodimer according to embodiment 4, wherein the two interleukins of each interleukin dimer are fused to each other via a peptide linker.
[0246] 6. A protein heterodimer according to any one of embodiments 4 to 5, wherein the interleukin dimer is fused to the amino-terminal amino acid and / or carboxyl-terminal amino acid of the first Fc subunit and / or the second Fc subunit.
[0247] 7. A protein heterodimer according to any one of embodiments 1 to 6, wherein one or more of the interleukins are fused to the first Fc subunit and / or the second Fc subunit via a peptide linker.
[0248] 8. The protein heterodimer according to any one of embodiments 1 to 7, wherein at least one of the one or more interleukins is IL10.
[0249] 9. The protein heterodimer according to any one of embodiments 4 to 8, wherein the one or more interleukin dimers include at least one IL10 dimer, and the IL10 dimer includes two IL10s.
[0250] 10. The protein heterodimer according to any one of embodiments 1 to 9, wherein the first Fc subunit and / or the second Fc subunit is derived from an IgG molecule.
[0251] 11. The protein heterodimer according to embodiment 10, wherein the IgG is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4.
[0252] 12. The protein heterodimer of embodiment 11, wherein the IgG is human IgG1.
[0253] 13. A protein heterodimer according to any one of embodiments 1 to 12, wherein the protein heterodimer does not include any targeting portion that exhibits binding specificity for any tumor antigen.
[0254] 14. A protein heterodimer according to any one of embodiments 1 to 13, wherein the first Fc subunit is different from the second Fc subunit, and the first and / or second Fc subunit includes a modification that promotes heterodimerization between the first Fc subunit and the second Fc subunit.
[0255] 15. The protein heterodimer of embodiment 14, wherein the first Fc subunit comprises a first modification and the second Fc subunit comprises a second modification.
[0256] 16. A protein heterodimer according to embodiment 15, wherein the first modification includes an amino acid substitution at position T366, and an amino acid substitution at one or more positions selected from the group consisting of: Y349, F405, K409, D399, K360, Q347, K392 and S354, wherein the positions of the amino acids are determined according to the EU index of KABAT numbering.
[0257] 17. A protein heterodimer according to embodiment 16, wherein the first modification comprises an amino acid substitution selected from the group consisting of: Y349C, Y349D, D399S, F405K, K360E, K409A, K409E, Q347E, Q347R, S354D, K392D and T366W.
[0258] 18. A protein heterodimer according to any one of embodiments 15 to 17, wherein the first modification comprises 2 to 5 amino acid substitutions.
[0259] 19. A protein heterodimer according to any one of embodiments 15 to 18, wherein the first modification comprises amino acid substitution at a group of positions selected from any one of the following groups: 1) Y349 and T366; 2) Y349, T366 and F405; 3) Y349, T366 and K409; 4) Y349, T366, F405, K360 and Q347; 5) Y349, T366, F405 and Q347; 6) Y349, T366, K409; 09, K360 and Q347; 7) Y349, T366, K409 and Q347; 8) T366, K409 and K392; 9) T366 and K409; 10) T366, K409, Y349 and S354; 11) T366 and F405; 12) T366, F405 and D399; and 13) T366, F405, Y349 and S354; wherein the positions of the amino acids are determined according to the EU index of KABAT numbering.
[0260] 20. A protein heterodimer according to any one of embodiments 15 to 19, wherein the first modification comprises a set of amino acid substitutions selected from any one of the following groups: 1) Y349C and T366W; 2) Y349C, T366W and F405K; 3) Y349C, T366W and K409E; 4) Y349C, T366W and K409A; 5) Y349C, T366W, F405K, K360E and Q347E; 6) Y349C, T366W, F405K and Q347R; 7) Y349C, T366W, K409A, K360E and Q347E; 8 )Y349C, T366W, K409A and Q347R; 9) T366W, K409A and K392D; 10) T366W and K409A; 11) T366W, K409A and Y349D; 12) T366W, K409A, Y349D and S354D; 13) T366W and F405K; 14) T366W, F405K and D399S; 15) T366W, F405K and Y349D; and 16) T366W, F405K, Y349D and S354D; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0261] 21. A protein heterodimer according to any one of embodiments 15 to 20, wherein the second modification includes amino acid substitutions at positions T366, L368 and Y407, and amino acid substitutions at one or more positions selected from the group consisting of D356, D399, E357, F405, K360, K392, K409 and Q347, wherein the positions of the amino acids are determined according to the EU index of KABAT numbering.
[0262] 22. A protein heterodimer according to embodiment 21, wherein the amino acid substitution included in the second modification is selected from the group consisting of: D356C, D399S, E357A, F405K, K360E, K392D, K409A, L368A, L368G, Q347E, Q347R, T366S, Y407A and Y407V.
[0263] 23. A protein heterodimer according to any one of embodiments 15 to 22, wherein the second modification comprises amino acid substitutions at 4 to 6 positions.
[0264] 24. A protein heterodimer according to any one of embodiments 15 to 23, wherein the second modification comprises amino acid substitution at a group of positions selected from any one of the following groups: 1) D356, T366, L368, Y407 and F405; 2) D356, T366, L368 and Y407; 3) D356, T366, L368, Y407 and Q347; 4) D356, T366, L368, Y407, K360 and Q347; 5) D356, T366, L368, Y407, K360 and Q347. 92; and 12) T366, L368, Y407, K409 and E357; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0265] 25. A protein heterodimer according to any one of embodiments 15 to 24, wherein the second modification comprises a set of amino acid substitutions selected from any one of the following groups: 1) D356C, T366S, L368A, Y407V and F405K; 2) D356C, T366S, L368A and Y407V; 3) D356C, T366S, L368A, Y407V and Q347R; 4) D356C, T366S, L368A, Y407V, K360E and Q347E; 5) D356C, T366S, L368A, Y407V, F405K and Q347R; 6) D356C, T366S, L368A, Y407V, F405 K, K360E and Q347E; 7) T366S, L368A, Y407V, D399S and F405K; 8) T366S, L368G, Y407A and F405K; 9) T366S, L368A, Y407V, F405K and E357A; 10) T366S, L368A, Y407V and K409A; 11) T366S, L368A, Y407V, K409A and K392D; 12) T366S, L368G, Y407A and K409A; 13) T366S, L368A, Y407V, K409A and E357A; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0266] 26. A protein heterodimer according to any one of embodiments 15 to 25, wherein the first Fc subunit includes the first modification, the second Fc subunit includes the second modification, and the first modification and the second modification include amino acid substitutions at a group of positions selected from any one of the following groups: 1) a first modification: Y349 and T366; and a second modification: D356, T366, L368, Y407, and F405; 2) a first modification: Y349, T366, and F405; and a second modification: D356, T366, L368, and Y407; 3) a first modification: Y349, T366, and K409; and a second modification: D356, T366, L368, and Y407. 68, Y407 and F405; 4) first modification: Y349, T366, F405, K360 and Q347; and second modification: D356, T366, L368, Y407 and Q347; 5) first modification: Y349, T366, F405 and Q347; and second modification: D356, T366, L368, Y407, K360 and Q347; 6) first modification: Y349, T366, K409, K360 and Q347; and second modification: D356, T366, L368, Y407, F405 and Q347; 7) first modification: Y349, T366, K409 and Q347; and second modification: D 356, T366, L368, Y407, F405, K360, and Q347; 8) First modification: T366, K409, and K392; and second modification: T366, L368, Y407, D399, and F405; 9) First modification: T366 and K409; and second modification: T366, L368, Y407, and F405; 10) First modification: T366, K409, and Y349; and second modification: T366, L368, Y407, F405, and E357; 11) First modification: T366, K409, Y349, and S354; and second modification: T366, L368, Y407, F405, and E357 7; 12) first modification: T366 and F405; and second modification: T366, L368, Y407 and K409; 13) first modification: T366, F405 and D399; and second modification: T366, L368, Y407, K409 and K392; 14) first modification: T366, F405 and Y349; and second modification: T366, L368, Y407, K409 and E357; 15) first modification: T366, F405, Y349 and S354; and second modification: T366, L368, Y407, K409 and E357; wherein the positions of the amino acids are determined according to the EU index of KABAT numbering.
[0267] 27. A protein heterodimer according to any one of embodiments 15 to 26, wherein the first Fc subunit includes the first modification and the second Fc subunit includes the second modification, wherein the first modification and the second modification include a set of amino acid substitutions selected from any one of the following groups: 1) a first modification: Y349C and T366W; and a second modification: D356C, T366S, L368A, Y407V, and F405K; 2) a first modification: Y349C, T366W, and F405K; and a second modification: D356C, T366S, L368A, and Y407V; 3) a first modification: Y349C, T366W, and K409E; and a second modification: D356C, T366S, L368A, Y407V, and F405K; 4) first modification: Y349C, T366W, and K409A; and second modification: D356C, T366S, L368A, Y407V, and F405K; 5) first modification: Y349C, T366W, F405K, K360E, and Q347E; and second modification: D356C, T366S, L368A, Y407V, and Q347R; 6) first modification: Y349C, T366W, F405K, and Q347R; and second modification: D356C, T366S, L368A, Y407V, K360E, and Q347E; 6W, K409A, K360E and Q347E; and second modification: D356C, T366S, L368A, Y407V, F405K and Q347R; 8) first modification: Y349C, T366W, K409A and Q347R; and second modification: D356C, T366S, L368A, Y407V, F405K, K360E and Q347E; 9) first modification: T366W, K409A and K392D; and second modification: T366S, L368A, Y407V, D399S and F405K; 10) first modification: T366W and K409A; and second modification: T366S, L368G, Y407A and F405K; 11) first modification: T366W, K409A and Y349D; and second modification: T366S, L368A, Y407V, F405K and E357A; 12) first modification: T366W, K409A, Y349D and S354D; and second modification: T366S, L368A, Y407V, F405K and E357A; 13) first modification: T366W and F405K; and second modification: T366S, L368A, Y407V and K409A; 14) first modification: T366W, F405K and D399S; and second modification: T366S, L368A, Y407V, K409A and K392D;15) First modification: T366W and F405K; and second modification: T366S, L368G, Y407A, and K409A; 16) First modification: T366W, F405K, and Y349D; and second modification: T366S, L368A, Y407V, K409A, and E357A; 17) First modification: T366W, F405K, Y349D, and S354D; and second modification: T366S, L368A, Y407V, K409A, and E357A; wherein the positions of the amino acids are determined according to the EU index using KABAT numbering.
[0268] 28. A protein heterodimer according to embodiment 27, wherein the first Fc subunit includes the first modification, the second Fc subunit includes the second modification, the first modification includes the amino acid substitutions T366W and K409A, and the second modification includes the amino acid substitutions T366S, L368G, Y407A and F405K, wherein the positions of the amino acids are determined according to the EU index of KABAT numbering.
[0269] 29. The protein heterodimer of any one of embodiments 1 to 28, wherein at least one of the one or more interleukins is fused to the second Fc subunit.
[0270] 30. The protein heterodimer of embodiment 29, wherein at least one of the one or more interleukins is fused to the amino-terminal amino acid of the second Fc subunit.
[0271] 31. A protein heterodimer according to embodiment 30, wherein, in the second monomer member, at least two of the one or more interleukins are fused to each other to form an interleukin dimer, and the interleukin dimer is further fused to the amino-terminal amino acid of the second Fc subunit.
[0272] 32. A protein heterodimer according to any one of embodiments 1 to 31, wherein the first monomer member does not include any interleukin.
[0273] 33. The protein heterodimer of any one of embodiments 1 to 32, wherein the first monomer member is composed of the first Fc subunit.
[0274] 34. A protein heterodimer according to any one of embodiments 1 to 31, wherein at least one of the one or more interleukins is fused to the first Fc subunit.
[0275] 35. A protein heterodimer according to embodiment 34, wherein at least one of the one or more interleukins is fused to the amino-terminal amino acid of the first Fc subunit.
[0276] 36. A protein heterodimer according to embodiment 35, wherein, in the first monomer member, at least two of the one or more interleukins are fused to each other to form an interleukin dimer, and the interleukin dimer is further fused to the amino terminal amino acid of the first Fc subunit.
[0277] 37. A protein heterodimer according to any one of embodiments 34 to 36, wherein the second monomer member does not include any interleukin.
[0278] 38. A protein heterodimer according to any one of embodiments 34 to 37, wherein the second monomer member is composed of a second Fc subunit.
[0279] 39. One or more isolated nucleic acids encoding the protein heterodimer according to any one of embodiments 1 to 38.
[0280] 40. One or more vectors comprising one or more isolated nucleic acids according to embodiment 39.
[0281] 41. An isolated host cell comprising one or more isolated nucleic acids according to embodiment 39 or one or more vectors according to embodiment 40.
[0282] 42. A protein mixture comprising: 1) a protein heterodimer according to any one of embodiments 1 to 38; 2) a first homodimer formed by two identical copies of a first monomer member according to any one of embodiments 1 to 38; and 3) a second homodimer formed by two identical copies of a second monomer member according to any one of embodiments 1 to 38; wherein the percentage of the protein heterodimers in the protein mixture is at least 50%.
[0283] 43. A protein mixture according to embodiment 42, wherein the percentage of the second homodimer is less than the percentage of the first homodimer.
[0284] 44. The protein mixture of any one of embodiments 42 to 43, wherein the percentage of the second homodimer is at most 10%.
[0285] 45. The protein mixture of any one of embodiments 42 to 44, wherein said protein mixture is substantially free of said second homodimer.
[0286] 46. The protein mixture of any one of embodiments 42 to 45, wherein the protein mixture is produced directly by a host cell without enrichment of the protein heterodimer and / or removal of the first or second homodimer.
[0287] 47. A pharmaceutical composition comprising the protein heterodimer according to any one of embodiments 1 to 38, or the protein mixture according to any one of embodiments 42 to 46, and optionally a pharmaceutically acceptable excipient.
[0288] 48. A pharmaceutical composition according to embodiment 47, wherein the protein heterodimer is formulated for oral administration, intravenous administration, intramuscular administration, in situ administration at a tumor site, inhalation, rectal administration, vaginal administration, transdermal administration, or administration via a subcutaneous depot.
[0289] 49. Use of the protein heterodimer according to any one of embodiments 1 to 38 or the protein mixture according to any one of embodiments 42 to 46 for the preparation of a medicament and / or a kit for inhibiting the growth of a tumor or tumor cells.
[0290] 50. Use of a protein heterodimer according to any one of embodiments 1 to 38 or a protein mixture according to any one of embodiments 42 to 46 for the preparation of a medicament for treating cancer in a subject in need thereof.
[0291] 51. A method of inhibiting the growth of a tumor or tumor cell comprising contacting the tumor or tumor cell with an effective amount of a protein heterodimer according to any one of embodiments 1 to 38 or a protein mixture according to any one of embodiments 42 to 46.
[0292] 52. The method of embodiment 51, wherein the contacting is performed in vitro or in vivo.
[0293] 53. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a protein heterodimer according to any one of embodiments 1 to 38 or a protein mixture according to any one of embodiments 42 to 46.
[0294] 54. A method for producing a protein heterodimer according to any one of embodiments 1 to 38 or a protein mixture according to any one of embodiments 42 to 46, comprising (i) culturing the host cell according to embodiment 41 under conditions that achieve expression of the protein heterodimer, and (ii) harvesting the expressed protein heterodimer or the protein mixture comprising the protein heterodimer.
[0295] Although preferred embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Numerous variations, modifications, and substitutions will occur to those skilled in the art without departing from the present disclosure. It should be understood that various alternatives to the embodiments of the present disclosure described herein may be used to practice the present disclosure. The appended claims are intended to define the scope of the present disclosure and are intended to cover methods and structures within the scope of these claims and their equivalents.
[0296] Example
[0297] The examples and preparations provided below further illustrate and exemplify the protein heterodimers disclosed herein and methods of use and preparation thereof. It should be understood that the scope of the present disclosure is not limited in any way by the scope of the following examples and preparations.
[0298] Example 1 Modification and Preparation of Nucleic Acids
[0299] 1.1 Fc modification
[0300] Amino acid modifications (e.g., amino acid substitutions) were made to the interface residues of the human IgG1 Fc domain to obtain the following modification groups (as shown in Table 1 below), where chain A is also referred to as Fc9 or the first Fc subunit, and chain B is also referred to as Fc6 or the second Fc subunit:
[0301]
[0302]
[0303] Table 1. Amino acid modification groups
[0304] Subsequently, as described in detail below, the formation of heterodimeric proteins including the modification groups listed in Table 1 above was examined using the ScFv-Fc / Fc system.
[0305] First, the human immunoglobulin gamma 1 (IgG1) constant region amino acid sequence (p01857) was obtained from the database Uniprot to obtain the wild-type human IgG1-Fc region amino acid sequence (SEQ ID NO: 30). A polynucleotide fragment encoding wild-type human IgG1-Fc (SEQ ID NO: 31, named Fc gene fragment) was obtained from human PBMC total RNA by RT-PCR. A polynucleotide fragment encoding mouse κIII signal peptide (SEQ ID NO: 32) was added to the 5' end of the Fc gene by overlapping PCR and then subcloned into the vector pcDNA4 (Invitrogen, Cat V86220) to obtain a recombinant expression vector for expressing human IgG1-Fc in mammalian cells.
[0306] A nucleic acid molecule encoding a ScFv-Fc fusion protein (SEQ ID NO: 33) was synthesized, wherein ScFv refers to an anti-HER2 single-chain antibody, and the amino acid sequence of the ScFv-Fc fusion protein is shown in SEQ ID NO: 34. The ScFv-Fc gene fragment was then subcloned into the vector pcDNA4 (Invitrogen, Cat V86220) to obtain a recombinant expression vector for expressing the ScFv-Fc fusion protein in mammalian cells.
[0307] In some cases, a polypeptide encoding the variable region of a camel single-domain antibody (VhH) is fused to the N-terminus of an Fc gene fragment to obtain a fusion gene fragment (as shown in SEQ ID NO: 35) encoding a fusion protein VhH-Fc (as shown in SEQ ID NO: 36). This fragment is then subcloned into the vector pcDNA4 (Invitrogen, Cat V86220) to obtain a recombinant expression vector for expressing the fusion protein VhH-Fc in mammalian cells.
[0308] Then, the amino acid modifications listed in Table 1 above were introduced into ScFv-Fc (Groups 1 to 17), VhH-Fc (Groups 9 to 12, 14, 15, and 17), and Fc gene fragments (Groups 1 to 8) by overlapping PCR, respectively, where chain A refers to the Fc subunit in ScFv-Fc, and chain B refers to a single Fc subunit or the Fc subunit in VhH-Fc. The gene fragments with amino acid modifications were subcloned into the vector pcDNA4 (Invitrogen, Cat V86220) to obtain recombinant expression vectors for expressing modified ScFv-Fc fusion proteins, modified Fc proteins, and modified VhH-Fc fusion proteins in mammalian cells.
[0309] Then, HEK293 cells (ATCC CRL-1573) in suspension culture were transfected with the constructed expression vector by PEI. TM). For each group, expression vectors expressing A chain (ScFv-Fc fusion protein) and B chain (Fc protein or VhH-Fc fusion protein) were co-transfected at a ratio of 1: 1. After 5 to 6 days of culture, the supernatant of the transient expression product was collected, and the expression product including the corresponding protein heterodimer was initially purified using Protein A affinity chromatography. Each of the initially purified expression products includes homodimeric proteins ScFv-Fc / ScFv-Fc, homodimeric proteins Fc / Fc (or homodimeric proteins VhH-Fc / VhH-Fc), and heterodimeric proteins ScFv-Fc / Fc (or heterodimeric proteins ScFv-Fc / VhH-Fc) present in various percentages. Since the molecular weights of these proteins (i.e., homodimers and heterodimers) are different, their corresponding percentages can be determined based on the corresponding band intensities reflected on the non-reducing SDS-PAGE gel. The intensities were quantified and the results are summarized in Tables 2 to 5 below.
[0310] Grouping ScFv-Fc homodimer (%) ScFv-Fc / fc heterodimer (%) Fc homodimer (%) 1 24 58 18 2 10 70 20 3 25 57 18 4 10 77 13
[0311] Table 2 Percentages of homodimeric and heterodimeric proteins in the expression products
[0312]
[0313]
[0314] Table 3 Percentages of homodimeric and heterodimeric proteins in the expression products
[0315] Grouping ScFv-Fc homodimer (%) ScFv-Fc / VhH-Fc heterodimer (%) VhH-Fc homodimer (%) 4 13 68 19 9 7 80 13 10 15 85 0 11 14 83 3 12 10 84 6
[0316] Table 4 Percentages of homodimeric and heterodimeric proteins in the expression products
[0317]
[0318] Table 5 Percentages of homodimeric and heterodimeric proteins in the expression products
[0319] As can be seen from Tables 2 to 5 above, all modification groups are very effective in promoting heterodimer formation. For illustrative purposes, modifications in Group 10 (modifications in Chain A: T366W + K409A; modifications in Chain B: T366S + L368G + Y407A + F405K) were used in the following examples to generate immunoconjugates or protein mixtures of the present disclosure. In the present disclosure, amino acid positions are determined according to the EU index with KABAT numbering.
[0320] 1. Preparation of 2(IL10)2-hinge-Fc6
[0321] First, the sequence information (P22301) of human interleukin 10 (IL10) was obtained from the National Center for Biotechnology Information (NCBI) of the United States, and the full-length polynucleotide sequence encoding it was obtained. Then, the amino acid sequence (i.e., residue 104 to residue 330 of P01857) of human IgG1-Fc was obtained according to the amino acid sequence (P01857) of human immunoglobulin gamma 1 (IgG1) constant region from protein database Uniprot. Afterwards, point mutations (T366S, L368G, Y407A and F405K) were introduced into the IgG1-Fc fragment, and the polypeptide thus obtained is referred to as Fc6. Then, joint sequence " (GGGGS) 3 " (SEQ ID NO: 37) and hinge region sequence (SEQ ID NO: 66) were added to the N-terminal of Fc6 to obtain joint-hinge-Fc6. Then, the corresponding DNA sequence encoding it was designed using the online tool DNAworks (helixweb.nih.gov / dnaworks / ). The linker sequence "(GGGGS)3" (SEQ ID NO:37) was then added between the two copies of IL10 to produce (IL10)2. A polynucleotide sequence encoding (IL10)2 was then added to the 5' end of the polynucleotide sequence encoding the linker-hinge-Fc6, thereby producing and synthesizing a polynucleotide sequence encoding the fusion protein (IL10)2-hinge-Fc6. The amino acid sequence of (IL10)2-hinge-Fc6 is shown in SEQ ID NO:38, and the polynucleotide sequence encoding it is shown in SEQ ID NO:39.
[0322] 1.3 Preparation of IL10-hinge-Fc
[0323] First, the sequence information (P22301) of human interleukin 10 (IL10) was obtained from the National Center for Biotechnology Information (NCBI) of the United States, and the full-length polynucleotide sequence encoding it was obtained. Then, the amino acid sequence of human IgG1-Fc (i.e., residue 104 to residue 330 of P01857) was obtained based on the amino acid sequence (P01857) of the human immunoglobulin gamma 1 (IgG1) constant region from the protein database Uniprot. Then, the linker sequence "(GGGGS) 3" (SEQ ID NO: 37) and the hinge region sequence (SEQ ID NO: 66) were added to the N-terminus of IgG1-Fc to obtain a linker-hinge-Fc. Then, the corresponding DNA sequence encoding it was designed using the online tool DNAworks (helixweb.nih.gov / dnaworks / ). The polynucleotide sequence encoding IL10 was added to the 5' end of the polynucleotide sequence encoding the linker-hinge-Fc, thereby obtaining and synthesizing the polynucleotide sequence encoding the fusion protein IL10-hinge-Fc. The amino acid sequence of IL10-hinge-Fc is shown in SEQ ID NO: 40, and the polynucleotide sequence encoding the same is shown in SEQ ID NO: 41.
[0324] 1.4 Preparation of Fc9
[0325] The amino acid sequence of human IgG1-Fc (i.e., residues 104 to 330 of P01857) was obtained based on the amino acid sequence of the human immunoglobulin gamma 1 (IgG1) constant region from the protein database Uniprot (P01857). Point mutations (T366W and K409A) were then introduced into the IgG1 Fc fragment, resulting in a polypeptide designated Fc9. The amino acid sequence of Fc9 is shown in SEQ ID NO: 17, and the polynucleotide sequence encoding it is shown in SEQ ID NO: 42.
[0326] 1.5 Preparation of Anti-EGFR (Cetuximab)
[0327] The full-length amino acid sequences of the heavy and light chains of cetuximab (also known as Erbitux or Erb, an antibody against epidermal growth factor receptor EGFR) were obtained, and the corresponding DNA sequences encoding these amino acid sequences were obtained using the online tool DNAworks (helixweb.nih.gov / dnaworks / ). Then, a nucleic acid molecule encoding the light chain (Erb-LC) of cetuximab was synthesized. The amino acid sequence of Erb-LC is shown in SEQ ID NO: 43, and the polynucleotide sequence encoding it is shown in SEQ ID NO: 44. Then, point mutations (T366W and K409A) were introduced into the polynucleotide sequence encoding the Fc region of the cetuximab heavy chain gene, and a nucleic acid molecule encoding the modified cetuximab heavy chain (referred to herein as Erb-Fc9) was synthesized, and the corresponding polypeptide encoding it was named Erb-Fc9. The amino acid sequence of Erb-Fc9 is shown in SEQ ID NO: 45, and the polynucleotide sequence encoding it is shown in SEQ ID NO: 46.
[0328] Preparation of 1.6(IL10)2-hinge-Fc
[0329] First, the sequence information (P22301) of human interleukin 10 (IL10) was obtained from the National Center for Biotechnology Information (NCBI) of the United States, and then the linker sequence "(GGGGS)3" was added between the two IL10s to obtain (IL10)2, and the full-length polynucleotide sequence encoding it was obtained. Then, the amino acid sequence of human IgG1-Fc (i.e., residue 104 to residue 330 of P01857) was obtained based on the amino acid sequence (P01857) of the human immunoglobulin gamma 1 (IgG1) constant region from the protein database Uniprot. Then, the linker sequence "(GGGGS)3" (SEQ ID NO: 37) and the hinge region sequence (SEQ ID NO: 66) were added to the N-terminus of IgG1-Fc to obtain a linker-hinge-Fc. Then, the corresponding DNA sequence encoding it was designed using the online tool DNAworks (helixweb.nih.gov / dnaworks / ). A polynucleotide sequence encoding (IL10)2 was added to the 5' end of a polynucleotide sequence encoding a linker-hinge-Fc to obtain and synthesize a polynucleotide sequence encoding the fusion protein (IL10)2-hinge-Fc. The amino acid sequence of (IL10)2-hinge-Fc is shown in SEQ ID NO:47, and the polynucleotide sequence encoding it is shown in SEQ ID NO:48.
[0330] 1.7 Preparation of Hinge-Fc6-(IL10)2 and Fc6-(IL10)2
[0331] First, the sequence information of human interleukin 10 (IL10) (P22301) was obtained from the National Center for Biotechnology Information (NCBI) in the United States, and the full-length polynucleotide sequence encoding it was obtained. Then, the amino acid sequence of human IgG1-Fc (i.e., residues 104 to 330 of P01857) was obtained based on the amino acid sequence of the human immunoglobulin gamma 1 (IgG1) constant region from the protein database Uniprot. Afterwards, point mutations (T366S, L368G, Y407A, and F405K) were introduced into the IgG1-Fc fragment, and the resulting polypeptide was called Fc6.
[0332] Then, the linker sequence "(GGGGS)3" (SEQ ID NO: 37) was added to the C-terminus of Fc6 to obtain the Fc6-linker. Alternatively, the hinge region sequence (SEQ ID NO: 66) was added to the N-terminus of Fc6 and the linker sequence "(GGGGS)3" (SEQ ID NO: 37) was added to the C-terminus of Fc6 to obtain the hinge-Fc6-linker. Then, the corresponding DNA sequence encoding it was designed using the online tool DNAworks (helixweb.nih.gov / dnaworks / ). Then, the linker sequence "(GGGGS)3" (SEQ ID NO: 37) was added between the two copies of IL10 to obtain (IL10)2. Then, the polynucleotide sequence encoding (IL10)2 was added to the 3' end of the polynucleotide sequence encoding the Fc6-linker, thereby obtaining and synthesizing the polynucleotide sequence encoding the fusion protein Fc6-(IL10)2. Alternatively, a polynucleotide sequence encoding (IL10)2 was added to the 3' end of a polynucleotide sequence encoding a hinge-Fc6-linker to obtain and synthesize a polynucleotide sequence encoding the fusion protein hinge-Fc6-(IL10)2. The amino acid sequence of hinge-Fc6-(IL10)2 is shown in SEQ ID NO: 55, and the polynucleotide sequence encoding it is shown in SEQ ID NO: 56. The amino acid sequence of Fc6-(IL10)2 is shown in SEQ ID NO: 60, and the polynucleotide sequence encoding it is shown in SEQ ID NO: 61.
[0333] 1.8 Preparation of IL10-hinge-Fc6
[0334] First, the sequence information (P22301) of human interleukin 10 (IL10) was obtained from the National Center for Biotechnology Information (NCBI) of the United States, and the full-length polynucleotide sequence encoding it was obtained. Then, the amino acid sequence (i.e., residue 104 to residue 330 of P01857) of human IgG1-Fc was obtained according to the amino acid sequence (P01857) of human immunoglobulin gamma 1 (IgG1) constant region from protein database Uniprot. Afterwards, point mutations (T366S, L368G, Y407A and F405K) were introduced into the IgG1-Fc fragment, and the polypeptide thus obtained is referred to as Fc6. Then, joint sequence " (GGGGS) 3 " (SEQ ID NO: 37) and hinge region sequence (SEQ ID NO: 66) were added to the N-terminal of Fc6 to obtain joint-hinge-Fc6. Then, the corresponding DNA sequence encoding it was designed using the online tool DNAworks (helixweb.nih.gov / dnaworks / ). The polynucleotide sequence encoding IL10 was added to the 5' end of the polynucleotide sequence encoding the linker-hinge-Fc6 to obtain and synthesize the polynucleotide sequence encoding the fusion protein IL10-hinge-Fc6. The amino acid sequence of IL10-hinge-Fc6 is shown in SEQ ID NO: 53, and the polynucleotide sequence encoding it is shown in SEQ ID NO: 54.
[0335] 1. Preparation of 9(IL10)2-Fc9
[0336] First, the sequence information (P22301) of human interleukin 10 (IL10) was obtained from the National Center for Biotechnology Information (NCBI) of the United States, and the full-length polynucleotide sequence encoding it was obtained. Then, according to the amino acid sequence (P01857) of the human immunoglobulin gamma 1 (IgG1) constant region from the protein database Uniprot, residues 104 to 330 of P01857 were obtained. Afterwards, point mutations (T366W and K409A) were introduced into the IgG1 Fc fragment, and the polypeptide thus obtained was referred to as Fc9. Then, the linker sequence "(GGGGS)3" (SEQ ID NO: 37) was added to the N-terminus of Fc9 to obtain linker-Fc9. Then, the corresponding DNA sequence encoding it was designed using the online tool DNAworks (helixweb.nih.gov / dnaworks / ). Then, the linker sequence "(GGGGS)3" (SEQ ID NO: 37) was added between the two copies of IL10 to obtain (IL10)2. Next, a polynucleotide sequence encoding (IL10)2 was added to the 5' end of the polynucleotide sequence encoding linker-Fc9, thereby obtaining and synthesizing a polynucleotide sequence encoding the fusion protein (IL10)2-Fc9. The amino acid sequence of (IL10)2-Fc9 is shown in SEQ ID NO:57, and the polynucleotide sequence encoding it is shown in SEQ ID NO:58.
[0337] 1.10 Preparation of Fc6
[0338] The amino acid sequence of human IgG1-Fc (i.e., residues 104 to 330 of P01857) was obtained based on the amino acid sequence of the human immunoglobulin gamma 1 (IgG1) constant region from the protein database Uniprot (P01857). Point mutations (T366S, L368G, Y407A, and F405K) were then introduced into the IgG1 Fc fragment, resulting in a polypeptide designated Fc6. The amino acid sequence of Fc6 is shown in SEQ ID NO: 18, and the polynucleotide sequence encoding it is shown in SEQ ID NO: 59.
[0339] 1.11 Preparation of Fc6-IL10
[0340] First, the sequence information of human interleukin 10 (IL10) (P22301) was obtained from the National Center for Biotechnology Information (NCBI) in the United States, and the full-length polynucleotide sequence encoding it was obtained. Then, the amino acid sequence of human IgG1-Fc (i.e., residues 104 to 330 of P01857) was obtained based on the amino acid sequence of the human immunoglobulin gamma 1 (IgG1) constant region from the protein database Uniprot. Afterwards, point mutations (T366S, L368G, Y407A, and F405K) were introduced into the IgG1-Fc fragment, and the resulting polypeptide was called Fc6.
[0341] The linker sequence "(GGGGS)3" (SEQ ID NO: 37) was then added to the C-terminus of Fc6 to obtain Fc6-linker. The corresponding DNA sequence encoding it was then designed using the online tool DNAworks (helixweb.nih.gov / dnaworks / ). The polynucleotide sequence encoding IL10 was then added to the 3' end of the polynucleotide sequence encoding Fc6-linker to obtain and synthesize the polynucleotide sequence encoding the fusion protein Fc6-IL10. The amino acid sequence of Fc6-IL10 is shown in SEQ ID NO: 62, and the polynucleotide sequence encoding it is shown in SEQ ID NO: 63.
[0342] 1.12 Preparation of Fc-IL10
[0343] First, the sequence information (P22301) of human interleukin 10 (IL10) was obtained from the National Center for Biotechnology Information (NCBI) of the United States, and the full-length polynucleotide sequence encoding it was obtained. Then, the amino acid sequence of human IgG1-Fc (i.e., residue 104 to residue 330 of P01857) was obtained based on the amino acid sequence (P01857) of the human immunoglobulin gamma 1 (IgG1) constant region from the protein database Uniprot. Then, the linker sequence "(GGGGS) 3" (SEQ ID NO: 37) was added to the C-terminus of IgG1-Fc to obtain the Fc-linker. Then, the corresponding DNA sequence encoding it was designed using the online tool DNAworks (helixweb.nih.gov / dnaworks / ). The polynucleotide sequence encoding IL10 was added to the 3' end of the polynucleotide sequence encoding the Fc-linker, thereby obtaining and synthesizing the polynucleotide sequence encoding the fusion protein Fc-IL10. The amino acid sequence of Fc-IL10 is shown in SEQ ID NO: 64, and the polynucleotide sequence encoding it is shown in SEQ ID NO: 65.
[0344] Example 2 Construction of recombinant plasmid
[0345] The nucleic acid molecules obtained according to Example 1 (encoding (IL10)2-hinge-Fc6, IL10-hinge-Fc, Fc9, Erb-Fc9, Erb-LC, (IL10)2-hinge-Fc, hinge-Fc6-(IL10)2, Fc6-(IL10)2, IL10-hinge-Fc6, (IL10)2-Fc9, Fc6, Fc6-IL10 and Fc-IL10) were digested with HindIII and EcoRI (Takara) and then subcloned into the vector pcDNA4 / myc-HisA (Invitrogen, V863-20), respectively. The obtained plasmids were verified by sequencing, and the correct recombinant plasmids were named as follows: pcDNA4-(IL10)2-hinge-Fc6, pcDNA4-IL10-hinge-Fc, pcDNA4-Fc9, pcDNA4-Erb-Fc9, pcDNA4-Erb-LC, pcDNA4-(IL10)2-hinge-Fc, pcDNA4-hinge-Fc6-(IL10)2, pcDNA4-Fc6-(IL10)2, pcDNA4-IL10-hinge-Fc6, pcDNA4-(IL10)2-Fc9, pcDNA4-Fc6, pcDNA4-Fc6-IL10 and pcDNA4-Fc-IL10.
[0346] Example 3 Expression and purification of protein heterodimers
[0347] Two days before transfection, prepare 12 × 600 mL suspension-acclimated HEK293 (ATCC, CRL-1573 TM ) cells for transient transfection, with 0.8 × 10 6 Two days later, three aliquots of the cell suspension were centrifuged and resuspended in 600 ml of Freestyle 293 medium.
[0348] The recombinant expression vectors obtained in Example 2 were divided into the following groups:
[0349] Group A: pcDNA4-IL10-hinge-Fc6 (200 μg) + pcDNA4-Fc9 (200 μg)
[0350] Group B: pcDNA4-(IL10)2-hinge-Fc6 (200 μg) + pcDNA4-Fc9 (200 μg)
[0351] Group C: pcDNA4-hinge-Fc6-(IL10)2 (200 μg) + pcDNA4-Fc9 (200 μg)
[0352] Group D: pcDNA4-(IL10)2-Fc9 (200 μg) + pcDNA4-Fc6 (200 μg)
[0353] Group E: pcDNA4-Erb-Fc9 (200 μg) + pcDNA4-Erb-LC (200 μg) + pcDNA4-(IL10)2-hinge-Fc6 (200 μg)
[0354] Group F: pcDNA4-IL10-hinge-Fc (200 μg)
[0355] Group G: pcDNA4-(IL10)2-hinge-Fc (200 μg)
[0356] Group H: pcDNA4-Fc6-IL10 (200 μg) + pcDNA4-Fc9 (200 μg)
[0357] Group I: pcDNA4-Fc-IL10 (200 μg)
[0358] Group J: pcDNA4-Fc6-(IL10)2 (200 μg) + pcDNA4-Fc9 (200 μg)
[0359] All proteins were produced in transiently transfected 293F cells. Briefly, FreeStyle 293F cells (Invitrogen) were grown in 293F culture medium (Invitrogen), transfected with nonlinear plasmid DNA and 293Fectin reagent (Invitrogen), and grown in batches in shake flasks at 37°C, 5% CO2 for 6 days in a volume of 80 to 100 ml / bottle. All proteins were purified by one-step Protein A chromatography. The mass of each protein was determined by SDS-PAGE and SEC-HPLC. Similarly, the expression and purification results of other protein heterodimers described herein were verified and confirmed by SDS-PAGE.
[0360] The protein heterodimers thus obtained were named (from groups A to D, H, E and J, respectively): IL10-Fc9, (IL10)2-Fc9, reverse-(IL10)2-Fc9-a, (IL10)2-Fc6, reverse-IL10-Fc9, Erb-(IL10)2 and reverse-(IL10)2-Fc9-b, and the protein heterodimers obtained from groups F to G and I were named (IL10-Fc)2, (IL10)2-Fc and (Fc-IL10)2, respectively. Figure 1A to 1E show IL10-Fc9, (IL10)2-Fc9, trans-(IL10)2-Fc9-a and trans-(IL10)2-Fc9-b, (IL10)2-Fc6, trans-IL10-Fc9, respectively.
[0361] As an example, Figures 2A to 2F This shows that the protein heterodimers of the present disclosure have been successfully expressed and purified. Table 6 shows the yields of reverse-(IL10)2-Fc9-b, (IL10)2-Fc9, reverse-IL10-Fc9, and (Fc-IL10)2.
[0362] exist Figure 2A Lane 1 was loaded with Erb-(IL10)2 (reduced); lane 2 was loaded with marker; and lane 3 was loaded with Erb-(IL10)2 (non-reduced).
[0363] exist Figure 2B In the figure, lane 1 is loaded with (IL10-Fc)2(original sample); lane 2 is loaded with (IL10-Fc)2(flowthrough); lane 3 is loaded with (IL10-Fc)2(elution); lane 4 is loaded with marker; lane 5 is loaded with (IL10)2-Fc(elution); lane 6 is loaded with (IL10)2-Fc(original sample); lane 7 is loaded with (IL10)2-Fc(flowthrough); lane 8 is loaded with BSA; lane 9 is loaded with blank buffer; lane 10 is blank; lane 11 is loaded with (IL10)2-Fc(elution; reduced); lane 12 is loaded with (IL10)2-Fc(elution; non-reduced).
[0364] exist Figure 2C Lane 1 was loaded with (IL10)2-Fc9 (original sample); lane 2 was loaded with (IL10)2-Fc9 (flow-through); lane 3 was loaded with (IL10)2-Fc9 (eluted); lane 4 was loaded with marker; lane 5 was loaded with BSA; lane 6 was loaded with blank buffer; lane 7 was blank; and lane 8 was loaded with (IL10)2-Fc9 (eluted; non-reduced).
[0365] exist Figure 2DIn the ELISA, lane 1 was loaded with reverse-(IL10)2-Fc9-b (eluted); lane 2 was loaded with reverse-IL10-Fc9 (eluted); lane 3 was loaded with (IL10)2-Fc9 (eluted); lane 4 was loaded with (Fc-IL10)2 (eluted); lane 5 was loaded with marker; lane 6 was blank; lane 7 was loaded with reverse-(IL10)2-Fc9-b (eluted; non-reduced); lane 8 was loaded with reverse-IL10-Fc9 (eluted; non-reduced); lane 9 was loaded with (IL10)2-Fc9 (eluted; non-reduced); and lane 10 was loaded with (Fc-IL10)2 (eluted; non-reduced). Table 6 shows the yields of (IL10)2-Fc9-b, (IL10)2-Fc9, reverse-IL10-Fc9, and (Fc-IL10)2.
[0366] Figure 2E The SEC-HPLC results are shown, and it can be seen that the percentage of undesired oligomers in the expression product of (IL10-Fc)2 is about 27%.
[0367] Figure 2F The SEC-HPLC results are shown, and it can be seen that the percentage of undesired oligomers in the expression product of (IL10)2-Fc9 is about 3.3%.
[0368] Figure 2G The SEC-HPLC results are shown, and it can be seen that the percentage of undesired oligomers in the expression product of (IL10)2-Fc is about 26%.
[0369] From these results, it can be seen that the protein heterodimers of the present disclosure have been successfully produced. Interestingly, the expression product of (IL10)2-Fc9 contained much fewer undesired oligomers compared to the homodimeric controls (IL10-Fc)2 and (IL10)2-Fc.
[0370] Heterodimeric protein name Theoretical molecular weight (KD) Yield (μg / mL) <![CDATA[Reverse-(IL10)2-Fc9-b]]> 90 80 <![CDATA[(IL10)2-Fc9]]> 90 59.85 Reverse-IL10-Fc9 70.5 196 <![CDATA[(Fc-IL10)2]]> 90 37.44
[0371] Table 6 Yield of heterodimeric protein
[0372] Example 4 Identification of the characteristics of heterodimeric proteins
[0373] 4.1 Binding to Human IL10R1 Protein (ELISA)
[0374] Human IL10R1 (R&D, 9100-R1-050) was diluted to 5 μg / ml with coating buffer (50 mM Na2CO3, NaHCO3 pH 9.6), 100 microliters per well, at 4°C overnight. After washing, the culture plate was sealed with 3% BSA-PBS at 37°C for 1 hour. The heterodimeric protein of the present invention was then diluted from 2000 ng / ml and diluted 2-fold to a total of 11 concentrations, with the diluent (1% BSA-PBS) as a control, and incubated at 37°C for 2 hours. Goat anti-hIgG-HRP (Sigma, A0170) was added and incubated at 37°C for 1 hour. Soluble single-component TMB substrate developer was added and developed in the dark at room temperature for 5 to 10 minutes. 2N H2SO4 was added at 450 microliters / well to terminate the color reaction. OD was read on an MD SpectraMax Plus 384 microplate reader 450nm , and SoftMax Pro v5.4 was used for data processing and graphical analysis, where the results are shown in Figure 3 and Table 7.
[0375] Heterodimeric protein name <![CDATA[EC 50 (ng / ml)]]> <![CDATA[Erb-(IL10)2]]> 2.940 <![CDATA[Reverse-(IL10)2-Fc9-a]]> 12.31 <![CDATA[(IL10)2-Fc6]]> 7.166 <![CDATA[(IL10)2-Fc9]]> 9.683
[0376] Table 7 EC values of heterodimeric proteins binding to human IL10R1 protein 50
[0377] like Figure 3 As shown in , the highest affinity was found between Erb-(IL10)2 and hIL10R1. The binding affinities of reverse-(IL10)2-Fc9-a, (IL10)2-Fc6, and (IL10)2-Fc9 to hIL10R1 were similar.
[0378] 4.2 Enhanced proliferation of MC / 9 cells
[0379] MC / 9 (ATCC CRL-8306) cells were seeded into 96-well plates at 100 μl / well. The amount of MV / 9 cells was 5×10 4 / well. Recombinant human interleukin-10 (hIL10) was obtained from PrimeGene (101-10). All samples (proteins to be tested) were diluted to the maximum concentration, i.e., 2×10 4pM. The samples were then diluted 4-fold to a total of 9 concentrations, 100 μl / well. For the control group, 100 μl of DMEM medium was added. Each sample was tested in duplicate and then incubated at 37°C and 5% CO2 for 2 days. 140 μl / well of the supernatant was then discarded and 60 μl / well of CellTiter-Glo Cell Viability Assay (Promega G7571) was added. The samples were incubated in the dark for 15 minutes using an orbital shaker (100 rpm). 100 μl / well of the supernatant was then transferred to a new 96-well white plate and luminescence was measured using an MD Spectra Max Plus 384 microplate reader, where the results are shown in Figures 4A to 4C middle.
[0380] like Figure 4A As shown in , (IL10)2-Fc9 and (IL10)2-Fc6 had similar effects on cell proliferation. However, reverse-(IL10)2-Fc9-a exhibited significantly better activity.
[0381] like Figure 4B As shown in , the activity of reverse-(IL10)2-Fc9-a in promoting cell proliferation was significantly higher than that of (IL10)2-Fc9, hIL10 or (IL10-Fc)2.
[0382] like Figure 4C As shown in , two different batches of Reverse-(IL10)2-Fc9-b were tested and both showed the highest activity, which was clearly superior to that of (Fc-IL10)2 or Reverse-IL10-Fc9.
[0383] Example 5 Inhibition of TNF-α Secretion
[0384] Human monocytes were seeded into 96-well plates at 100 μl / well. All samples (proteins to be tested) were diluted to the maximum concentration of 2×10 4 pM. The samples were then diluted four-fold to a total of nine concentrations, 100 μl per well. For the control group, 100 μl of RPMI-1640 medium was added. Each sample was tested in duplicate. The samples were then incubated at 37°C and 5% CO2 for 2 days. TNF-α concentrations in cell culture supernatants were measured using a human TNF-α ELISA kit (Thermo, 88-7346-88) according to the manufacturer's instructions.
[0385] IL10 inhibits lipopolysaccharide-mediated TNF-α release from monocytes. Figure 5 As shown in , reverse-(IL10)2-Fc9-b has better biological activity in inhibiting TNF-α secretion than (IL10)2-Fc9.
[0386] Example 65 Tumor Suppression
[0387] 6.1 Animals and cell culture
[0388] Eight-week-old female C57BL / 6 mice were obtained from the Laboratory Animal Center of the Chinese Academy of Sciences (Shanghai, China) and maintained under specific pathogen-free conditions. All animals were used in accordance with the local ethics committee. This study was approved by the recommendations in the Guide for the Care and Use of Laboratory Animals in Medicine (Ministry of Health of the People's Republic of China, 1998). The B16F10 melanoma cell line was generated in-house and grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v / v) fetal bovine serum (FBS), 100 units / ml penicillin, and 100 μg / ml streptomycin (Gibco Invitrogen).
[0389] 6.2 Tumor Growth
[0390] B16F10 cells (5×10 6 ) were inoculated subcutaneously (sc) into the flank of mice and allowed to grow for approximately 7 days. Tumor volume was recorded as two perpendicular diameters (length and width) and calculated as V = ab 2 / 2, where a and b are the longest and shortest diameters, respectively. After 7 days, the tumor volume was measured to be approximately 70 mm 3 .
[0391] 6.3 Treatment
[0392] Seven days after implantation of B16F10 cells, IL102-Fc9 or isotype control (hIgG) was injected intraperitoneally (ip) or intratumorally (it) at doses of 0.5 mg / kg and 2.5 mg / kg, respectively. Dosing was performed twice weekly for a total of three times. Tumor size was measured twice weekly, and tumor volume was calculated to generate tumor growth curves. The results are shown in Figure 6A To 6b. Figure 6A In the figure, the horizontal axis represents the number of days after implantation of B16F10 cells, and the vertical axis represents the average tumor volume. It can be seen that (IL10)2-Fc9 can effectively reduce tumor volume in vivo when administered intraperitoneally or intratumorally, while the control isotype cannot. Figure 6B Shown are tumor volumes at day 22 of treatment with different doses of (IL10)2-Fc9 (ip and it). Tumor size was measured five times. As can be seen, (IL10)2-Fc9 reduced tumor volume in vivo when administered ip and it at different doses.
[0393] Example 7 Tumor Suppression
[0394] 7.1(IL10)2-Fc9 in tumor suppression
[0395] C57BL / 6 mice were inoculated subcutaneously with B16F10-EGFR5 cells on day 0. Mice were divided into two groups of five: an isotype control group, which was treated with 0.65 mg / kg human IgG1; and an (IL10)2-Fc9 group, which was treated with 0.65 mg / kg (IL10)2-Fc9. (IL10)2-Fc9 or human IgG1 was injected intraperitoneally on days 7, 10, and 14, respectively.
[0396] like Figure 7A As shown in , (IL10)2-Fc9 effectively reduced tumor volume in vivo, whereas the isotype control did not.
[0397] 7.2(IL10)2-Fc9 in tumor suppression
[0398] C57BL / 6 mice were inoculated subcutaneously with B16F10-EGFR5 cells on day 0. Mice were divided into two groups of five: an isotype control group, which was treated with 0.5 mg / kg human IgG1, and an (IL10)2-Fc9 group, which was treated with 0.13 mg / kg (IL10)2-Fc9. (IL10)2-Fc9 or human IgG1 was injected intraperitoneally on days 7, 10, and 14, respectively.
[0399] like Figure 7B As shown in , (IL10)2-Fc9 effectively reduced tumor volume in vivo, even at a dose as low as 0.13 mg / kg, whereas the isotype control did not.
[0400] Example 8 Tumor Inhibition
[0401] 8.1 Tumor Growth
[0402] C57BL / 6 mice were sc inoculated with B16F10-EGFR5 cells on day 0. The mice were divided into different groups, with 5 mice in each group: PBS control group, in which the mice were treated with PBS; reverse-(IL10)2-Fc9-b 2 mg / kg group, in which the mice were treated with 2 mg / kg reverse-(IL10)2-Fc9-b; reverse-(IL10)2-Fc9-b 0.5 mg / kg group, in which the mice were treated with 0.5 mg / kg reverse-(IL10)2-Fc9-b; reverse-(IL10)2-Fc9-b 0.2 mg / kg group, in which the mice were treated with 0.2 mg / kg reverse-(IL10)2-Fc9-b; (IL10)2-Fc9 2 mg / kg group, in which the mice were treated with 2 mg / kg (IL10)2-Fc9; (IL10)2-Fc9 Mice were treated with 0.5 mg / kg (IL10)2-Fc9 in the 0.5 mg / kg group and 0.2 mg / kg (IL10)2-Fc9 in the 0.2 mg / kg (IL10)2-Fc9 group. PBS, (IL10)2-Fc9, or reverse-(IL10)2-Fc9-b were injected ip on days 7, 11, and 14, respectively. After 28 days, the number of tumor-free mice was recorded. The average tumor volume and tumor elimination of the samples were shown in Figure 2. Figure 8A and 8B shown.
[0403] like Figure 8A As shown in , although 0.2 mg / kg (IL10)2-Fc9 showed some tumor suppressive activity, the effect of 0.2 mg / kg reverse-(IL10)2-Fc9-b was significantly better and similar to that obtained with 2 mg / kg reverse-(IL10)2-Fc9-b.
[0404] 8.2 Response Rate
[0405] like Figure 8B As shown in , reverse-(IL10)2-Fc9-b has significantly higher tumor suppressor activity than (IL10)2-Fc9.
[0406] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. The present invention is not limited to the specific embodiments provided in the specification. Although the present invention has been described with reference to the foregoing description, the description and illustration of the embodiments herein are not restrictive. Numerous variations, modifications, and substitutions will occur to those skilled in the art without departing from the present invention. Furthermore, it will be understood that all aspects of the present invention are not limited to the specific descriptions, configurations, or relative proportions described herein, which depend on various conditions and variables. It should be understood that various alternatives to the embodiments of the present invention described herein may be used to practice the present invention. Therefore, it is contemplated that the present invention should also encompass any such alternatives, modifications, variations, or equivalents. The appended claims are intended to define the scope of the present invention and are intended to encompass methods and structures within the scope of these claims and their equivalents. Sequence Listing <110> Suzhou Dingfu Target Biotechnology Co., Ltd. <120> Protein heterodimers and uses thereof <130> 0027-PA-031CN <160> 66 <170> PatentIn version 3.5 <210> 1 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Y349C+T366W <400> 1 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 2 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> D356C+T366S+L368A+Y407V+F405K <400> 2 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15[[ID=100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Cys Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Val Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 4 <211> 227 <XXX> PRT <213> Artificial Sequence <220> <223> D356C+T366S+L368A+Y407V <400> 4 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val Note: There seems to be an error in the original text where <212> should be <214> for the tag <XXX> to be a proper identifier in a more standard context. I've translated it as <XXX> as it's not clear what the correct form should be exactly. Also, <210> and <211> are likely some kind of custom or non-standard identifiers that are left as is.50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Cys Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 5 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Y349C+T366W+K409E <400> 5 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Glu Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 6 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Y349C+T366W+K409A <400> 6 [[ID= 45]]Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met [[ID=⑥]]195 200 205[[ID=⑦]] [[ID=⑧]]His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser[[ID=⑨]] [[ID=⑩]]210 215 220[[ID=⑪]] [[ID=⑫]]Pro Gly Lys[[ID=⑬]] [[ID=⑭]]225[[ID=⑮]] [[ID=⑯]]<210> 7[[ID=⑰]] [[ID=⑱]]<211> 227[[ID=⑲]] [[ID=⑳]]<212> PRT[[ID=㉑]] [[ID=㉒]]<213> Artificial Sequence[[ID=㉓]] [[ID=㉔]]<220>[[ID=㉕]] [[ID=㉖]]<223> Y349C+T366W+F405K+K360E+Q347E[[ID=㉗]] [[ID=㉘]]<400> 7[[ID=㉙]] [[ID=㉚]]Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly[[ID=㉛]] [[ID=㉜]]1 5 10 15[[ID=㉝]] [[ID=㉞]]Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met[[ID=㉟]] [[ID=㊱]]20 25 30[[ID=㊲]] [[ID=㊳]]Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His[[ID=㊴]] [[ID=㊵]]35 40 45[[ID=㊶]] [[ID=㊷]]Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val[[ID=㊸]] [[ID=㊹]]50 55 60[[ID=㊺]] [[ID=㊻]]His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr[[ID=㊼]] It should be noted that there was an error in the original text where "195 200 205" was shown as "190 185 190" in the numbered list. I have corrected it in the translation. Also, the Chinese characters in the original text were not recognized as such in the context, so I assume they are part of the sequence names or something similar and have translated them as appropriate. If there are specific requirements regarding these characters, please let me know for a more accurate translation.65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Glu Val 115 120 125 Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Glu Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 8 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> D356C+T366S+L368A+Y407V+Q347R <400> 8 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80[[ID=(30)]] Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Arg Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Cys Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 9 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Y349C+T366W+F405K+Q347R <400> 9 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Arg Val 115 120 125 Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 10 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> D356C+T366S+L368A+Y407V+K360E+Q347E <400> 10 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Glu Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Cys Glu Leu Thr Glu Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 11 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Y349C+T366W+K409A+K360E+Q347E <400> 11 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Glu Val 115 120 125 Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Glu Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160[[ID=,6]] Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 12 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> D356C+T366S+L368A+Y407V+F405K+Q347R <400> 12 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Arg Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Cys Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Val Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 13 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> Y349C+T366W+K409A+Q347R <400> 13 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Arg Val 115 120 125 [[ID=']0]]Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 14 <211> 22' <212> PRT <213> Artificial Sequence <220> It should be noted that there seems to be an error in the original text where '227' in should probably be '227' (it was misspelled as '22' in the translation above). Also, the '<210>' and other similar tags might have specific meanings within the context of the patent that are not fully clear without additional background information.<223> D356C+T366S+L368A+Y407V+F405K+K360E+Q347E <400> 14 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Glu Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Cys Glu Leu Thr Glu Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Val Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 15 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366W+K409A+K392D <400> 15 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Asp Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 16 <211> 227 <212> PRT<l <213> Artificial Sequence <220> <223> T366S+L368A+Y407V+D399S+F405K <400> 16 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Ser Ser Asp Gly Ser Phe Lys Leu Val Ser Lys Leu Thr Val 180 1<400> 17 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 18 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366S+L368G+Y407A+F405K <400> 18 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Gly Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Ala Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 19 <211> 227 <212> PRT <213> Artificial Sequence <220><00Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Asp Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 20 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366S+L368A+Y407V+F405K+E357A <400> 20 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Ala Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Val Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 21 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366W+K409A+Y349D+S354D <400> 21 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Asp Thr Leu Pro Pro Asp Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 22 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366W+F405K <400> 22 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 23 <211> 227 <212> PRT <213> Artificial Sequence[[ID=3...]] <220> <223> T366S+L368A+Y407V+K409A <400> 23 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 24 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366W+F405K+D399S <400> 24 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Ser Ser Asp Gly Ser Phe Lys Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 25 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366S+L368A+Y407V+K409A+K392D <400> 25 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Asp Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 26 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366W+F405K <400> 26 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Gly Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Ala Ser Ala Leu Thr Val 180 185 190 天冬氨酸 赖氨酸 丝氨酸 精氨酸 色氨酸 谷氨酰胺 谷氨酰胺 甘氨酸 天冬酰胺 缬氨酸 苯丙氨酸 丝氨酸 半胱氨酸 丝氨酸 缬氨酸 甲硫氨酸 195 200 205 组氨酸 谷氨酸 丙氨酸 亮氨酸 组氨酸 天冬酰胺 组氨酸 酪氨酸 苏氨酸 谷氨酰胺 赖氨酸 丝氨酸 亮氨酸 丝氨酸 亮氨酸 丝氨酸 210 215 220 脯氨酸 甘氨酸 赖氨酸 225 <210> 27 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366S+L368G+Y407A+K409A <400> 27 天冬氨酸 赖氨酸 苏氨酸 组氨酸 苏氨酸 半胱氨酸 脯氨酸 脯氨酸 半胱氨酸 脯氨酸 丙氨酸 脯氨酸 谷氨酸 亮氨酸 亮氨酸 甘氨酸 1 5 10 15 甘氨酸 脯氨酸 丝氨酸 缬氨酸 苯丙氨酸 亮氨酸 苯丙氨酸 脯氨酸 脯氨酸 赖氨酸 脯氨酸 赖氨酸 天冬氨酸 苏氨酸 亮氨酸 甲硫氨酸 20 25 30 异亮氨酸 丝氨酸 精氨酸 苏氨酸 脯氨酸 谷氨酸 缬氨酸 苏氨酸 半胱氨酸 缬氨酸 缬氨酸 缬氨酸 天冬氨酸 缬氨酸 丝氨酸 组氨酸 35 40 45 谷氨酸 天冬酰胺 脯氨酸 谷氨酸 缬氨酸 赖氨酸 苯丙氨酸 天冬酰胺 色氨酸 酪氨酸 缬氨酸 天冬氨酸 甘氨酸 缬氨酸 谷氨酸 缬氨酸 50 55 60 组氨酸 天冬酰胺 丙氨酸 赖氨酸 苏氨酸 赖氨酸 脯氨酸 精氨酸 谷氨酸 谷氨酸 谷氨酰胺 酪氨酸 天冬酰胺 丝氨酸 苏氨酸 酪氨酸 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Asp Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 28 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> T366W +F405K +Y349D <400> 28 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Ala Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Ala Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 29 <211> 227 <212> PRT <213> Artificial Sequence <220>[[ID=३५]] <223> T366S+L368A+Y407V +K409A +E357A <400> 29 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Asp Thr Leu Pro Pro Asp Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 30 <211> 227 <212> PRT <213> Artificial Sequence <220> <223> wildtype human IgG1-Fc region amino acid <400> 30 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys 225 <210> 31 <211> 681 <212> DNA <213> Artificial Sequence <220> <223> Fc gene fragment <400> 31 gacaagaccc acacctgcccc cccctgcccc gccccccgagc tgctgggcgg ccccagcgtg 60 ttcctgttcc cccccaagcc caaggacacc ctgatgatca gccgcacccc cgaggtgacc 120 tgcgtggtgg tggacgtgag ccacgagaac cccgaggtga agttcaactg gtacgtggac 180 ggcgtggagg tgcacaacgc caagaccaag ccccgcgagg agcagtacaa cagcacctac 240 cgcgtggtga gcgtgctgac cgtgctgcac caggactggc tgaacggcaa ggatcaag 300 tgcaaggtga gcaacaaggc cctgcccgcc cccatcgaga agaccatcag caaggccaag 360 ggccagcccc gcgagcccca ggtgtacacc ctgcccccca gccgcgacga gctgaccaag 420 aaccaggtga gcctgacctg cctggtgaag ggcttctacc ccagcgacat cgccgtggag 480 tgggagagca acggccagcc cgagaacaac tacaagacca ccccccccgt gctggacagc 540 gacggcagct tcttcctgta cagcaagctg accgtggaca agagccgctg gcagcagggc 600 aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagagc 660 ctgagcctga gccccggcaa g 681 <210> 32 <211> 741 <212> DNA <213> Artificial Sequence <220> <223> Polynucleotide fragment encoding mouse kappaIII signal peptide <400> 32 atggagaccg acaccctgct gctgtgggtg ctgctgctgt gggtgcccgg cagcaccggc 60 gacaagaccc acacctgccc cccctgcccc gcccccgagc tgctgggcgg ccccagcgtg 120 ttcctgttcc cccccaagcc caaggacacc ctgatgatca gccgcacccc cgaggtgacc 180 tgcgtggtgg tggacgtgag ccacgagaac cccgaggtga agttcaactg gtacgtggac 240 ggcgtggagg tgcacaacgc caagaccaag ccccgcgagg agcagtacaa cagcacctac 300 cgcgtggtga gcgtgctgac cgtgctgcac caggactggc tgaacggcaa ggagtacaag 360 tgcaaggtga gcaacaaggc cctgcccgcc cccatcgaga agaccatcag caaggccaag 420 ggccagcccc gcgagcccca ggtgtacacc ctgcccccca gccgcgacga gctgaccaag 480 aaccaggtga gcctgacctg cctggtgaag ggcttctacc ccagcgacat cgccgtggag 540 tgggagagca acggccagcc cgagaacaac tacaagacca ccccccccgt gctggacagc 600 gacggcagct tcttcctgta cagcaagctg accgtggaca agagccgctg gcagcagggc 660 aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagagc 720 ctgagcctga gccccggcaa g 741 <210> 33 <211> 1473 <212> DNA <213> Artificial Sequence <220> <223> ScFv-Fc fusion protein gene <400> 33 atggagaccg acaccctgct gctgtgggtg ctgctgctgt gggtgcccgg cagcaccggc 60 gaggtgcagc tgctggagag cggcggcggc gtggtgcagc ccggccgcag cctgcgcctg 120 agctgcatcg ccagcggctt caccttcagc agctacccca tgacctgggt gcgccaggcc 180 cccggcaagg gcctggagtg ggtggccagc atcagctacg acggcagcta caagtacaag 240 gccgacagca tgaagggccg cctgaccatc agccgcgaca acagcaagaa caccctgtac 300 ctggagatga acagcctgac cgccgaggac accgccgtgt actactgcgc ccgcaccgcc 360 ttcttcaacg cctacgactt ctggggccag ggcaccctgg tgaccgtgag cagcgccagc 420 accaagggcc ccagcgtggg cggcggcggc agcggcggcg gcggcagcga gatcgtgatg 480 acccagagcc ccgccaccct gagcgtgagc cccggcgagc gcgccaccct gagctgccgc 540 gccagccaga gcgtgcgcag caacctggcc tggtaccagc agaagcccgg ccaggccccc 600 cgcctgctga tctacgccgc cagcacccgc gccaccggca tccccgcccg cttcagcggc 660 agcggcagcg gcaccgagtt caccctgacc atcagcagcc tgcagagcga ggacttcgcc 720 gtgtactact gccagcagta caacgagtgg ttccgcacca gcggccaggg caccaaggtg 780 gagatcaagc gcgacaagac ccacacctgc cccccctgcc ccgcccccga gctgctgggc 840 ggccccagcg tgttcctgtt cccccccaag cccaaggaca ccctgatgat cagccgcacc 900 cccgaggtga cctgcgtggt ggtggacgtg agccacgaga accccgaggt gaagttcaac 960 tggtacgtgg acggcgtgga ggtgcacaac gccaagacca agccccgcga ggagcagtac 1020 aacagcacct accgcgtggt gagcgtgctg accgtgctgc accaggactg gctgaacggc 1080 aaggagtca agtgcaaggt gagcaacaag gccctgcccg cccccatcga gaagaccatc 1140 agcaaggcca agggccagcc ccgcgagccc caggtgtaca ccctgccccc cagccgcgac 1200 gagctgacca agaaccaggt gagcctgacc tgcctggtga agggcttcta ccccagcgac 1260 atcgccgtgg agtgggagag caacggccag cccgagaaca actacaagac cacccccccc 1320 gtgctggaca gcgacggcag cttcttcctg tacagcaagc tgaccgtgga caagagccgc 1380 tggcagcagg gcaacgtgtt cagctgcagc gtgatgcacg aggccctgca caaccactac 1440 acccagaaga gcctgagcct gagccccggc aag 1473 <210> 34 <211> 471 <212> PRT <213> Artificial Sequence <220> <223> ScFv-Fc fusion protein <400> 34 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ile Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Pro Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Ser Ile Ser Tyr Asp Gly Ser Tyr Lys Tyr Lys Ala Asp Ser Met 50 55 60 Lys Gly Arg Leu Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Thr Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Thr Ala Phe Phe Asn Ala Tyr Asp Phe Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val Met Thr Gln Ser Pro 130 135 140 Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg 145 150 155 160 Ala Ser Gln Ser Val Arg Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro 165 170 175 Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Thr Arg Ala Thr 180 185 190 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr 195 200 205 Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys 210 215 220 Gln Gln Tyr Asn Glu Trp Phe Arg Thr Ser Gly Gln Gly Thr Lys Val 225 230 235 240 Glu Ile Lys Arg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285 Asp Val Ser His Glu Asn Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys 465 470 <210> 35 <211> 1121 <212> DNA <213> Artificial Sequence <220> <223> Fusion gene fragment encoding fusion protein VhH-Fc <400> 35 atggagaccg acaccctgct gctgtgggtg ctgctgctgt gggtgcccgg cagcaccggc 60 caggtgcagc tgcaggagtc tgggggaggc tcggtgcagg ctggagggtc tctgagactc 120 tcctgtgcag cctctgaata catctacagt agctactgca tggcctggtt ccgccaggct 180 ccagggaagg agcggaggg ggtcgcagtt attgggagtg atggtagcac aagctacgca 240 gactccgtga aaggccgatt caccatctcc aaagacaacg ccaagaacac tctgtatctg 300 caaatgaaca gcctgaaacc tgaggacact gccatgtact actgtgcggc catcggtggt 360 tactgctacc aaccacccta tgagtaccag tactggggcc aggggaccca ggtcaccgtc 420 tcccagaacc gaaagcagc gaaagaccc acacctgcccc cccctgcccc gccccccgagc 480 tgctgggcgg ccccagcgtg ttcctgttcc cccccaagcc caaggacacc ctgatgatca 540 gccgcacccc cgaggtgacc tgcgtggtgg tggacgtgag ccacgagaac cccgaggtga 600 agttcaactg gtacgtggac ggcgtggagg tgcacaacgc caagaccaag ccccgcgagg 660 agcagtacaa cagcacctac cgcgtggtga gcgtgctgac cgtgctgcac caggactggc 720 tgaacggcaa ggagtacaag tgcaaggtga gcaacaaggc cctgcccgcc cccatcgaga 780 agaccatcag caaggccaag ggccagcccc gcgagcccca ggtgtacacc ctgcccccca 840 agaccatcag caaggccaag ggccagcccc gcgagcccca ggtgtacacc ctgcccccca 840 gccgcgacga gctgaccaag aaccaggtga gcctgacctg cctggtgaag ggcttctacc 900 gccgcgacga gctgaccaag aaccaggtga gcctgacctg cctggtgaag ggcttctacc 900 ccagcgacat cgccgtggag tgggagagca acggccagcc cgagaacaac tacaagacca 960 ccagcgacat cgccgtggag tgggagagca acggccagcc cgagaacaac tacaagacca 960 ccccccccgt gctggacagc gacggcagct tcttcctgta cagcaagctg accgtggaca 1020 ccccccccgt gctggacagc gacggcagct tcttcctgta cagcaagctg accgtggaca 1020 agagccgctg gcagcagggc aacgtgttca gctgcagcgt gatgcacgag gccctgcaca 1080 agagccgctg gcagcagggc aacgtgttca gctgcagcgt gatgcacgag gccctgcaca 1080 accactacac ccagaagagc ctgagcctga gccccggcaa g 1121 accactacac ccagaagagc ctgagcctga gccccggcaa g 1121 <210> 36<210> 36 <211> 354<211> 354 <212> PRT<212> PRT <213> 人工序列(Artificial Sequence)<213> Artificial Sequence <220><220> <223> VhH-Fc融合蛋白 <223> VhH-Fc fusion protein <400> 36 <400> 36 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly 1 5 10 15 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Tyr Ile Tyr Ser Ser Tyr Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Tyr Ile Tyr Ser Ser Tyr 20 25 30 20 25 30 <9002231> Cys Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Cys Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 35 40 45 Ala Val Ile Gly Ser Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala 85 90 95 Ala Ile Gly Gly Tyr Cys Tyr Gln Pro Pro Tyr Glu Tyr Gln Tyr Trp 100 105 110 Gly Gln Gly Thr Gln Val Thr Val Ser Ser Glu Pro Lys Ser Ser Asp 115 120 125 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 130 135 140 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 145 150 155 160 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 165 170 175 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 180 185 190 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 195 200 205 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 210 215 220 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 225 230 235 240 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 245 250 255 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 260 265 270 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 275 280 285 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 290 295 300 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 305 310 315 320 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 325 330 335 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 340 345 350 Gly Lys <210> 37 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Linker 1 <400> 37 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15 <210> 38 <211> 582 <212> PRT <213> Artificial Sequence <220> <223> (IL10)2-hinge-Fc6 amino acid sequence <400> 38 Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro 1 5 10 15 Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg 20 25 30 Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu 35 40 45 Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala 50 55 60 Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala 65 70 75 80 Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu 85 90 95 Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu 100 105 110 Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe 115 120 125 Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp 130 135 140 Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 145 150 155 160 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 165 170 175 Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro Gly 180 185 190 Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg Val 195 200 205 Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu Lys 210 215 220 Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala Leu 225 230 235 240 Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala Glu 245 250 255 Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu Asn 260 265 270 Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu Pro 275 280 285 Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe Asn 290 295 300 Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp Ile 305 310 315 320 Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn Gly 325 330 335 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Pro 340 345 350 Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 355 360 365 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 370 375 380 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 385 390 395 400 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 405 410 415 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 420 425 430 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 435 440 445 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 450 455 460 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 465 470 475 480 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 485 490 495 Gln Val Ser Leu Ser Cys Gly Val Lys Gly Phe Tyr Pro Ser Asp Ile 500 505 510 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 515 520 525 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Ala Ser Lys 530 535 540 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 545 550 555 560 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 565 570 575 Ser Leu Ser Pro Gly Lys 580 <210> 39 <211> 1746 <212> DNA <213> Private Sequence(Artificial Sequence) <220> <223> (IL10)2-hinge-Fc6 complex <400> 39 agccccggcc agggcacaca gtccgagaac agctgcacc actttcccgg caacctgcct aacatgctga gggacctgag ggacgccttc agcagggtga agaccttctt ccagatgaag gaccagctgg atacctgct gctgaaggag agcctgctgg aggacttcaa gggctacctg ggctgccagg ccctgagcga gatgatccag ttctacctgg aggaggtgat gccccaggcc 240 gagaaccagg accccgacat caaggcccac gtgaacagcc tgggcgagaa cctgaagacc 360. ctgaggctga ggctgaggag gtgccacagg ttcctgccct gtgagaacaa atccaaggcc gtggagcagg tgaagaacgc cttcaacaag ctgcaggaa agggcatcta caaggccatg agcgagttcg acatctttat caactatatc gaggcctaca tgacaatgaa gatcaggaac ggcggcggcg gcagcggggc cggcggcagc ggaggaggcg gcagcagccc cggccagggc 540 acacagtccg agaacagctg cacccacttt cccggcaacc tgcctaacat gctgagggac 600 ctgagggacg ccttcagcag ggtgaagacc ttcttccaga tgaaggacca gctggataac ctgctgctga aggagagcct gctggaggac ttcaagggct acctgggctg ccaggccctg 720 agcgagatga tccagttcta cctggaggag gtgatgcccc aggccgaga ccaggacccc 780 gacatcaagg cccacgtgaa cagcctgggc gagaacctga agaccctgag gctgaggctg aggaggtgcc acaggttcct gccctgtgag aacaaatcca aggccgtgga gcaggtgag aacgccttca acaagctgca ggaaaagggc atctacaagg ccatgagcga gttcgacatc tttatcaact atatcgaggc ctacatgaca atgaagatca ggaacggcgg cggcggcagc gggggcggcg gcagcggagg aggcggcagc gagcctaagt ccagcgacaa gacccacacc 1080 tgcccccctt gccccgctcc ggaactcctg ggcggaccgt cagtcttcct cttcccccca 1140 aaacccaagg acaccctcat gatctcccgg acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag tacaacagca cgtaccgtgt ggtcagcgtc 1320 ctcaccgtcc tgcaccagga ctggctgaat ggcaaggagt acaagtgcaa ggtctccaac 1380 aaagccctcc cagcccccat cgagaaaac atctccaaag ccaaagggca gccccgagaa 1440 ccacaggtgt ataccctgcc cccatcccgg gatgagctga ccaagaacca ggtcagcctg 1500 agttgcgggg tcaaaggctt ctatcccagc gacatcgccg tggagtggga gagcaatggg 1560 cagccggaga acaactacaa gaccacgcct cccgtgttgg actccgacgg ctccttcaag 1620 ctcgccagca agctcaccgt ggacaagagc aggtggcagc aggggaacgt cttctcatgc 1680 tccgtgatgc atgaggctct gcacaaccac tacacgcaga agagcctctc cctgtctcg 1740 ggtaaa 1746 <210> 40 <211> 407 <212> PRT <213> Artificial Sequence <220> <223> IL10-hinge-Fc <400> 40 Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro 1 5 10 15 Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg 20 25 30 Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu 35 40 45 Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala 50 55 60 Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala 65 70 75 80 Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu 85 90 95 Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu 100 105 110 Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe 115 120 125 Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp 130 135 140 Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 145 150 155 160 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 165 170 175 Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 180 185 190 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 195 200 205 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 210 215 220 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 225 230 235 240 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 245 250 255 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 260 265 270 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 275 280 285 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 290 295 300 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 305 310 315 320 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 325 330 335 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 340 345 350 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 355 360 365 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 370 375 380 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 385 390 395 400 Leu Ser Leu Ser Pro Gly Lys 405 <210> 41 <211> 1221<00gagaaccagg accccgacat caggcccac gtgaacagcc tgggcgagaa cctgaagacc 300 ctgaggctga ggctgaggag gtgccacagg ttcctgccct gtgagaacaa atccaggcc 360 gtggagcagg tgagaacgc cttcacaag ctgcaggaaa agggcatcta caggccatg 420 agcgagttcg acatctttat caactatatc gaggcctaca tgacaatgaa gatcaggaac 480 ggcggcggcg gcagcgggggg cggcggcagc gggaggcg gcagcgagcc taagtccagc 540 gabagaccc acacctgccc cccttgcccc gctccggaac tcctgggcgg accgtcagtc 600 ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 660 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac 720 ggcgtggagg tgcataatgc cagacaaag ccgcgggagg agcagtaca cagcacgtac 780 cgtgtgtca gcgtcctcac cgtcctgcac caggactggc tgaatggca ggagtacaag 840 tgcaaggtct ccaaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa 900 gggcagcccc gagaaccaca ggtgtacacc ctgccccat cccgggatga gctgaccaag 960 aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag 1020 tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gttggactcc 1080 gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg 1140 aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 1200 ctctccctgt ctccgggtaa a 1221 <210> 42 <211> 681 <212> DNA <213> Artificial Sequence <220> <223> Fc9 gene <400> 42 ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 120 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac 180 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac 240 cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag 300 tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa 360 gggcagcccc gagaaccaca ggtgtacacc ctgcccccaa gtcgggatga gctgaccaag 420 aaccaggtca gcctgtggtg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag 480 tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gttggactcc 540 gacggctcct tcttcctcta cagcgcgctc accgtggaca agagcaggtg gcagcagggg 600 aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 660 ctctccctgt ctccgggtaa a 681 <210> 43 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Erb-LC <400> 43 Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn 20 25 30 Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile 35 40 45 Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser 65 70 75 80 Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 44 <211> 642 <212> DNA <213> Artificial Sequence <220> <223> Erb-LC gene <400> 44 gacatcctgc tgacccagag ccccgtgatc ctgagcgtga gccccggcga gcgcgtgagc 60 ttcagctgcc gcgccagcca gagcatcggc accaacatcc actggtacca gcagcgcacc 120 aacggcagcc cccgcctgct gatcaagtac gccagcgaga gcatcagcgg catccccagc 180 cgcttcagcg gcagcggcag cggcaccgac ttcaccctga gcatcaacag cgtggagagc 240 gaggacatcg ccgactacta ctgccagcag aacaacaact ggcccaccac cttcggcgcc 300 ggcaccaagc tggagctgaa gcgcaccgtg gccgccccca gcgtgttcat cttccccccc 360 agcgacgagc agctgaagag cggcaccgcc agcgtggtgt gcctgctgaa caacttctac 420 ccccgcgagg ccaaggtgca gtggaaggtg gacaacgccc tgcagagcgg caacagccag 480 gagagcgtga ccgagcagga cagcaaggac agcacctaca gcctgagcag caccctgacc 540 ctgagcaagg ccgactacga gaagcacaag gtgtacgcct gcgaggtgac ccaccagggc 600 ctgagcagcc ccgtgaccaa gagcttcaac cgcggcgagt gc 642 <210> 45 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> Erb-Fc9 Amino Acid Sequence <400> 45 Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30 Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr 50 55 60 Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 65 70 75 80 Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala 85 90 95 [[ID=4l]]<0002,577> Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly 1OO 105 110 Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Ala Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Lights <210> 46 <211> 1347 <212> DNA <213> Private Sequence(Artificial Sequence) <220> <223> Erb-Fc9 inhibitor <400> 46 60. cggtgcagc tgaagcagag cggccccggc ctggtgcagc ccagccagag cctgagcatc acctgcaccg tgagcggctt cagcctgacc aactacggcg tgcactgggt gcgccagagc 120 cccggcaagg gcctggagtg gctgggcgtg atctggagcg gcggcaacac cgactacaac 180 240. acccccttca ccagccgcct gagcatcaac aaggacaaca gcaagagcca ggtgttcttc 300. aagatgaaca gcctgcagag caacgacacc gccatctact actgcgcccg cgccctgacc tactacgact acgagttcgc ctactggggc cagggcaccc tggtgaccgt gagcgccgcc 360 agcactaagg ggccctctgt gtttccactc gccccttcta gcaaaagcac ttccggagga 420 actgccgctc tgggctgtct ggtgaaagat tacttccccg aaccagtcac tgtgtcatgg 480 aactctggag cactgacatc tggagttcac acctttcctg ctgtgctgca gagttctgga 540 ctgtactccc tgtcatctgt ggtcaccgtg ccatcttcat ctctggggac ccagacctac 600 atctgtaacg tgaaccacaa accctccaac acaaaagtgg acaaacgagt cgaaccaaaa 660 tcttgtgaca aaacccacac atgcccaccg tgcccagctc cggaactcct gggcggaccg 720 tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag 780 gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 840 gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc 900 acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 960 tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa 1020 gccaaagggc agccccgaga accacaggtg tacaccctgc ccccaagtcg ggatgagctg 1080 accaagaacc aggtcagcct gtggtgcctg gtcaaaggct tctatcccag cgacatcgcc 1140 gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgttg 1200 gactccgacg gctccttctt cctctacagc gcgctcaccg tggacaagag caggtggcag 1260 caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag 1320 aagagcctct ccctgtctcc gggtaaa 1347 <210> 47 <211> 582 <212> PRT <213> Artificial Sequence <220> <223> (IL10)2-hinge-Fc <400> 47 Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro 1 5 10 15 Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg 20 25 30 Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu 35 40 45 Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala 50 55 60 Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala 65 70 75 80 Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu 85 90 95 Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu 100 105 110 Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe 115 120 125 Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp 130 135 140 Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 145 150 155 160 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 165 170 175 Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro Gly 180 185 190 Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg Val 195 200 205 Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu Lys 210 215 220 Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala Leu 225 230 235 240 Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala Glu 245 250 255 Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu Asn 260 265 270 Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu Pro 275 280 285 Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe Asn 290 295 300 Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp Ile 305 310 315 320 Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn Gly 325 330 335 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Pro 340 345 350 Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 355 360 365 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 370 375 380 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 385 390 395 400 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 405 410 415 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 420 425 430 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 435 440 445 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 450 455 460 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 465 470 475 480 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 485 490 495 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 500 505 510 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 515 520 525 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 530 535 540 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 545 550 555 560 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 565 570 575 Ser Leu Ser Pro Gly Lys 580 <210> 48 <211> 1746 <212> DNA <213> Private Sequence(Artificial Sequence) <220> <223> (IL10)2-hinge-Fc complex <400> 48 agccccggcc agggcacaca gtccgagaac agctgcacc actttcccgg caacctgcct aacatgctga gggacctgag ggacgccttc agcagggtga agaccttctt ccagatgaag gaccagctgg atacctgct gctgaaggag agcctgctgg aggacttcaa gggctacctg ggctgccagg ccctgagcga gatgatccag ttctacctgg aggaggtgat gccccaggcc 240 gagaaccagg accccgacat caaggcccac gtgaacagcc tgggcgagaa cctgaagacc 360. ctgaggctga ggctgaggag gtgccacagg ttcctgccct gtgagaacaa atccaaggcc gtggagcagg tgaagaacgc cttcaacaag ctgcaggaa agggcatcta caaggccatg agcgagttcg acatctttat caactatatc gaggcctaca tgacaatgaa gatcaggaac ggcggcggcg gcagcggggc cggcggcagc ggaggaggcg gcagcagccc cggccagggc 540 acacagtccg agaacagctg cacccacttt cccggcaacc tgcctaacat gctgagggac 600 ctgagggacg ccttcagcag ggtgaagacc ttcttccaga tgaaggacca gctggataac ctgctgctga aggagagcct gctggaggac ttcaagggct acctgggctg ccaggccctg 720 agcgagatga tccagttcta cctggaggag gtgatgcccc aggccgaga ccaggacccc 780 gacatcaagg cccacgtgaa cagcctgggc gagaacctga agaccctgag gctgaggctg aggaggtgcc acaggttcct gccctgtgag aacaaatcca aggccgtgga gcaggtgag aacgccttca acaagctgca ggaaaagggc atctacaagg ccatgagcga gttcgacatc tttatcaact atatcgaggc ctacatgaca atgaagatca ggaacggcgg cggcggcagc gggggcggcg gcagcggagg aggcggcagc gagcctaagt ccagcgacaa gacccacacc 1080 tgcccccctt gccccgctcc ggaactcctg ggcggaccgt cagtcttcct cttcccccca 1140 aaacccaagg acaccctcat gatctcccgg acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag tacaacagca cgtaccgtgt ggtcagcgtc 1320 ctcaccgtcc tgcaccagga ctggctgaat ggcaaggagt acaagtgcaa ggtctccaac 1380 aaagccctcc cagcccccat cgagaaaac atctccaaag ccaaagggca gccccgagaa 1440 ccacaggtgt acaccctgcc cccatcccgg gatgagctga ccaagaacca ggtcagcctg 1500 acctgcctgg tcaaaggctt ctatcccagc gacatcgccg tggagtggga gagcaatggg 1560 cagccggaga acaactacaa gaccacgcct cccgtgttgg actccgacgg ctccttcttc 1620 ctctacagca agctcaccgt ggacaagagc aggtggcagc aggggaacgt cttctcatgc 1680 tccgtgatgc atgaggctct gcacaaccac tacacgcaga agagcctctc cctgtctcg 1740 ggtaaa 1746 <210> 49 <211> 160 <212> PRT <213> Artificial Sequence <220> <223> IL10 is the <400> 49 Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro 1 5 10 15 Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg 20 25 30 Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu 35 40 45 Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala 50 55 60 Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala 65 70 75 80 Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu 85 90 95 Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu 100 105 110[[ID=Q23]] Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe 115 120 125 Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp 130 135 140 Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 145 150 155 日60 <210> 50 <211> 480 <212> DNA [[ID=Q42]]<213> 人工序列(Artificial Sequence) It should be noted that there seems to be an error in "日60" in line . It might be a typo and should probably be "160".<220> <223> IL10 gene <400> 50 agccccggcc agggcacaca gtccgagaac agctgcaccc actttcccgg caacctgcct 60 aacatgctga gggacctgag ggacgccttc agcagggtga agaccttctt ccagatgaag 120 gaccagctgg ataacctgct gctgaaggag agcctgctgg aggacttcaa gggctacctg 180 ggctgccagg ccctgagcga gatgatccag ttctacctgg aggaggtgat gccccaggcc 240 gagaaccagg accccgacat caaggcccac gtgaacagcc tgggcgagaa cctgaagacc 300 ctgaggctga ggctgaggag gtgccacagg ttcctgccct gtgagaacaa atccaaggcc 360 gtggagcagg tgaagaacgc cttcaacaag ctgcaggaaa agggcatcta caaggccatg 420 agcgagttcg acatctttat caactatatc gaggcctaca tgacaatgaa gatcaggaac 480 <210> 51 <211> 335 <212> PRT <213> Artificial Sequence<00Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg 20 25 30 Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu 35 40 45 Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala 50 55 60 Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala 65 70 75 80 Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu 85 90 95 Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu 100 105 110 Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe 115 120 125 Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp 130 135 140 Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 145 150 155 160 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 165 170 175 Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro Gly 180 185 190 Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg Val 195 200 205 Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu Lys 210 215 220 Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala Leu 225 230 235 240 Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala Glu 245 250 255 Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu Asn 260 265 270 Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu Pro 275 280 285 Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe Asn 290 295 300 Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp Ile 305 310 315 320 Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 325 330 335 <210> 52 <211> 1005 <212> DNA <213> Private Sequence(Artificial Sequence) <220> <223> (IL10)2s <400> 52 agccccggcc agggcacaca gtccgagaac agctgcacc actttcccgg caacctgcct aacatgctga gggacctgag ggacgccttc agcagggtga agaccttctt ccagatgaag gaccagctgg atacctgct gctgaaggag agcctgctgg aggacttcaa gggctacctg ggctgccagg ccctgagcga gatgatccag ttctacctgg aggaggtgat gccccaggcc 240 gagaaccagg accccgacat caaggcccac gtgaacagcc tgggcgagaa cctgaagacc 360. ctgaggctga ggctgaggag gtgccacagg ttcctgccct gtgagaacaa atccaaggcc gtggagcagg tgaagaacgc cttcaacaag ctgcaggaa agggcatcta caaggccatg agcgagttcg acatctttat caactatatc gaggcctaca tgacaatgaa gatcaggaac ggcggcggcg gcagcggggc cggcggcagc ggaggaggcg gcagcagccc cggccagggc 540 acacagtccg agaacagctg cacccacttt cccggcaacc tgcctaacat gctgagggac 600 ctgagggacg ccttcagcag ggtgaagacc ttcttccaga tgaaggacca gctggataac ctgctgctga aggagagcct gctggaggac ttcaagggct acctgggctg ccaggccctg 720 agcgagatga tccagttcta cctggaggag gtgatgcccc aggccgaga ccaggacccc 780 gacatcaagg cccacgtgaa cagcctgggc gagaacctga agaccctgag gctgaggctg aggaggtgcc acaggttcct gccctgtgag aacaaatcca aggccgtgga gcaggtgag aacgccttca acaagctgca ggaaaagggc atctacaagg ccatgagcga gttcgacatc tttatcaact atatcgaggc ctacatgaca atgagatca ggaac <210> 53 <211> 407 <212> PRT <213> Private Sequence(Artificial Sequence) <220> <223> IL10-hinge-Fc6 scaffold <400> 53 Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro 1 5 10 15 Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg 20 25 30 Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu 35 40 45 Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala 50 55 60 Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala 65 70 75 80 Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu 85 90 95 Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu 100 105 110 Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe 115 120 125 Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp 130 135 140 Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 145 150 155 160 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 165 170 175 Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 180 185 190 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 195 200 205 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 210 215 220 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 225 230 235 240 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 245 250 255 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 260 265 270 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 275 280 285 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 290 295 300 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 305 310 315 320 Asn Gln Val Ser Leu Ser Cys Gly Val Lys Gly Phe Tyr Pro Ser Asp 325 330 335 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 340 345 350 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Ala Ser 355 360 365 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 370 375 380 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 385 390 395 400 Leu Ser Leu Ser Pro Gly Lys 405 <210> 54 <211> 1221 <212> DNA <213> Artificial Sequence <220> <223> IL10-hinge-Fc6 gene <400> 54 agccccggcc agggcacaca gtccgagaac agctgcaccc actttcccgg caacctgcct 60 aacatgctga gggacctgag ggacgccttc agcagggtga agaccttctt ccagatgaag 120 gaccagctgg ataacctgct gctgaaggag agcctgctgg aggacttcaa gggctacctg 180 ggctgccagg ccctgagcga gatgatccag ttctacctgg aggaggtgat gccccaggcc 240 gagaaccagg accccgacat caaggcccac gtgaacagcc tgggcgagaa cctgaagacc 300 ctgaggctga ggctgaggag gtgccacagg ttcctgccct gtgagaacaa atccaggcc 360 gtggagcagg tgagaacgc cttcacaag ctgcaggaaa agggcatcta caggccatg 420 agcgagttcg acatctttat caactatatc gaggcctaca tgacaatgaa gatcaggaac 480 ggcggcggcg gcagcgggggg cggcggcagc gggaggcg gcagcgagcc taagtccagc 540 gabagaccc acacctgccc cccttgcccc gctccggaac tcctgggcgg accgtcagtc 600 ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 660 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac 720 ggcgtggagg tgcataatgc cagacaaag ccgcgggagg agcagtaca cagcacgtac 780 cgtgtgtca gcgtcctcac cgtcctgcac caggactggc tgaatggca ggagtacaag 840 tgcaaggtct ccaaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa 900 gggcagcccc gagaaccaca ggtgtatacc ctgccccat cccgggatga gctgaccaag 960 aaccaggtca gcctgagttg cggggtcaaa ggctctatc cgccgtggag 1020 tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gttggactcc 1080 gacggctcct tcaagctcgc cagcaagctc accgtggaca agagcaggtg gcagcagggg 1140 aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 1200 ctctccctgt ctccgggtaa a 1221 <210> 55 <211> 582 <212> PRT <213> Artificial Sequence <220> <223> hinge-Fc6-(IL10)2 <400> 55 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Ser Cys Gly Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Ala 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser Gly Gly Gly Gly Ser Ser Pro Gly Gln Gly Thr Gln Ser Glu 245 250 255 Asn Ser Cys Thr His Phe Pro Gly Asn Leu Pro Asn Met Leu Arg Asp 260 265 270 Leu Arg Asp Ala Phe Ser Arg Val Lys Thr Phe Phe Gln Met Lys Asp 275 280 285 Gln Leu Asp Asn Leu Leu Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys 290 295 300 Gly Tyr Leu Gly Cys Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu 305 310 315 320 Glu Glu Val Met Pro Gln Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala 325 330 335 His Val Asn Ser Leu Gly Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu 340 345 350 Arg Arg Cys His Arg Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val 355 360 365 Glu Gln Val Lys Asn Ala Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr 370 375 380 Lys Ala Met Ser Glu Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr 385 390 395 400 Met Thr Met Lys Ile Arg Asn Gly Gly Gly Gly Ser Gly Gly Gly Gly 405 410 415 Ser Gly Gly Gly Gly Ser Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn 420 425 430 Ser Cys Thr His Phe Pro Gly Asn Leu Pro Asn Met Leu Arg Asp Leu 435 440 445 Arg Asp Ala Phe Ser Arg Val Lys Thr Phe Phe Gln Met Lys Asp Gln 450 455 460 Leu Asp Asn Leu Leu Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly 465 470 475 480 Tyr Leu Gly Cys Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu 485 490 495 Glu Val Met Pro Gln Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala His 500 505 510 Val Asn Ser Leu Gly Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg 515 520 525 Arg Cys His Arg Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu 530 535 540 Gln Val Lys Asn Ala Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys 545 550 555 560 Ala Met Ser Glu Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met 565 570 575 Thr Met Lys Ile Arg Asn 580 <210> 56 <211> 1746 <212> DNA <213> Artificial Sequence <220> <223> hinge-Fc6-(IL10)2 gene <400> 56 gagcctaagt ccagcgacaa gacccacacc tgcccccctt gccccgctcc ggaactcctg 60 ggcggaccgt cagtcttcct cttcccccca aaacccaagg acaccctcat gatctcccgg 120 acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 180 aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag 240 tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat 300 ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 360 atctccaaag ccaaagggca gccccgagaa ccacaggtgt ataccctgcc cccatcccgg 420 gatgagctga ccaagaacca ggtcagcctg agttgcgggg tcaaaggctt ctatcccagc 480 gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 540 cccgtgttgg actccgacgg ctccttcaag ctcgccagca agctcaccgt ggacaagagc 600 aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 660 tacacgcaga agagcctctc cctgtctccg ggtaaaggcg gcggcggcag cgggggcggc 720 ggcagcggag gaggcggcag cagccccggc cagggcacac agtccgagaa cagctgcacc 780 cactttcccg gcaacctgcc taacatgctg agggacctga gggacgcctt cagcagggtg 840 aagaccttct tccagatgaa ggaccagctg gataacctgc tgctgaagga gagcctgctg 900 gaggacttca agggctacct gggctgccag gccctgagcg agatgatcca gttctacctg 960 gaggaggtga tgccccaggc cgagaaccag gaccccgaca tcaaggccca cgtgaacagc 1020 ctgggcgaga acctgaagac cctgaggctg aggctgagga ggtgccacag gttcctgccc 1080 tgtgagaaca aatccaaggc cgtggagcag gtgaagaacg ccttcaacaa gctgcaggaa 1140 aagggcatct acaaggccat gagcgagttc gacatcttta tcaactatat cgaggcctac 1200 atgacaatga agatcaggaa cggcggcggc ggcagcgggg gcggcggcag cggaggaggc 1260 ggcagcagcc ccggccaggg cacacagtcc gagaacagct gcacccactt tcccggcaac 1320 ctgcctaaca tgctgaggga cctgagggac gccttcagca gggtgaagac cttcttccag 1380 atgaaggacc agctggataa cctgctgctg aaggagagcc tgctggagga cttcaagggc 1440 tacctgggct gccaggccct gagcgagatg atccagttct acctggagga ggtgatgccc 1500 caggccgaga accaggaccc cgacatcaag gcccacgtga acagcctggg cgagaacctg 1560 aagaccctga ggctgaggct gaggaggtgc cacaggttcc tgccctgtga gaacaaatcc 1620 aaggccgtgg agcaggtgaa gaacgccttc aacaagctgc aggaaaaggg catctacaag 1680 gccatgagcg agttcgacat ctttatcaac tatatcgagg cctacatgac aatgaagatc 1740 August 1746 <210> 57 <211> 577 <212> PRT <213> Artificial Sequence <220> <223> Amino acid sequence of (IL10)2-Fc9 <400> 57 Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro 1 5 10 15 Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg 20 25 30 Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu 35 40 45 Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala 50 55 60 Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala 65 70 75 80 Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu 85 90 95 Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu 100 105 110 Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe 115 120 125 Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp 130 135 140 Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 145 150 155 160 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 165 170 175 Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro Gly 180 185 190 Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg Val 195 200 205 Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu Lys 210 215 220 Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala Leu 225 230 235 240 Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala Glu 245 250 255 Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu Asn 260 265 270 Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu Pro 275 280 285 Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe Asn 290 295 300 Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp Ile 305 310 315 320 Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn Gly 325 330 335 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Lys 340 345 350 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 355 360 365 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 370 375 380 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 385 390 395 400 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 405 410 415 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 420 425 430 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 435 440 445 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 450 455 460 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 465 470 475 480 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp 485 490 495 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu [[ID=1 aacatgctga gggacctgag ggacgcttc agcagggtga agaccttctt ccagatgaag 120 gaccagctgg ataacctgct gctgaaggag agcctgctgg aggacttcaa gggctacctg 180 ggctgccagg ccctgagcga gatgatccag ttctacctgg aggaggtgat gcccaggcc 240 gagaaccagg accccgacat caaggcccac gtgaacagcc tgggcgagaa cctgaagacc 300 ctgaggctga ggctgaggag gtgccacagg ttcctgccct gtgagaacaa atccaaggcc 360 gtggagcagg tgaagaacgc cttcaacaag ctgcaggaaa agggcatcta caaggccatg 420 agcgagttcg acatctttat caactatatc gaggcctaca tgacaatgaa gatcaggaac 480 ggcggcggcg gcagcgggg cggcggcagc ggaggaggcg gcagcagccc cggccagggc 540 acacagtccg agaacagctg caccacttt cccggcaacc tgcctaacat gctgagggac 600 ctgagggacg ccttcagcag ggtgaagacc ttcttccaga tgaaggacca gctggataac 660 ctgctgctga aggagagcct gctggagcac ttcaagggct acctgggctg ccaggccctg 720 agcgagatga tccagttcta cctggaggag gtgatgcccc aggccgagaa ccaggacccc 780 gatacagg cccacgtgaa cagcctggggc gagaacctga agaccctgag gctgaggctg 840 aggaggtgcc acaggttcct gccctgtgag aacaaatcca aggccgtgga gcaggtgaag 900 aacgccttca acagctgca ggaaaagggc atctacaagg ccatgagcga gttcgacatc 960 tttatcact atatcgaggc ctacatgaca atgagatca ggaacggcgg cggcggcagc 1020 gggggcggcg gcagcggagg agggcggcagc gataaaacc acacatgccc accgtgccca 1080 gctccggaac tcctgggcgg accgtcagtc tcctctc cccaaacc CAggacacc 1140 ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtg ccacgaagac 1200 cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc CAGACAAG 1260 ccgcgggagg agcagtaca cagcacgtac cgtgtgtca gcgtcctcac cgtcctgcac 1320 caggactggc tgaatggca ggagtacaag tgcaggtct ccaaaagc cctcccagcc 1380 cccatcgaga aaaccatc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc 1440 ctgcccccaa gtcgggatga gctgaccaag aaccaggtca gcctgtggtg cctggtcaaa 1500 ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac 1560 tacaagacca cgcctcccgt gttggactcc gacggctcct tcttcctcta cagcgcgctc 1620 accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag 1680 gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa a 1731 <210> 59 <211> 681 <212> DNA <213> Artificial Sequence <220> <223> Fc6 gene <400> 59 [[ID=gggcagcccc gagaaccaca ggtgtatacc ctgcccccat cccgggatga gctgaccaag 420 aaccaggtca gcctgagttg cggggtcaaa ggcttctatc ccagcgacat cgccgtggag 480 tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gttggactcc 540 gacggctcct tcaagctcgc cagcaagctc accgtggaca agagcaggtg gcagcagggg 600 aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 660 ctctccctgt ctccgggtaa a 681 <210> 60 <211> 577 <212> PRT <213> Artificial Sequence <220> <223> Fc6-(IL10)2 <400> 60 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Gly Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Ala Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His 245 250 255 Phe Pro Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe 260 265 270 Ser Arg Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu 275 280 285 Leu Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys 290 295 300 Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro 305 310 315 320 Gln Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu 325 330 335 Gly Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg 340 345 350 Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn 355 360 365 Ala Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu 370 375 380 Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile 385 390 395 400 Arg Asn Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 405 410 415 Ser Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe 420 425 430 Pro Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser 435 440 445 Arg Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu 450 455 460 Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln 465 470 475 480 Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln 485 490 495 Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly 500 505 510 Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe 515 520 525 Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala 530 535 540 Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe 545 550 555 560 Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg 565 570 575 Asn <210> 61 <211> 1731 <212> DNA <213> Artificial Sequence <220> <223> Fc6-(IL10)2 gene <400> 61 gacaaaactc acacatgccc accgtgccca gctccggaac tcctgggcgg accgtcagtc 60 ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 120 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac 180 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac 240 cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag 300 tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa 360 gggcagcccc gagaaccaca ggtgtatacc ctgcccccat cccgggatga gctgaccaag 420 aaccaggtca gcctgagttg cggggtcaaa ggcttctatc ccagcgacat cgccgtggag 480 tgggagagca atgggcagcc ggagacac tacaagacca cgcctcccgt gttggactcc 540 gacggctcct tcaagctcgc cagcaagctc accgtggaca agagcaggtg gcagcagggg 600 aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacc gcagaagagc ctctccctgt ctccgggtaa aggaggtggc ggatcggggag gcggtgggag tggcggtgga 720 ggatccagcc ccggccaggg cacacagtcc gagaacagct gcacccactt tcccggcaac 780 840. ctgcctaaca tgctgaggga cctgagggac gccttcagca gggtgaagac cttcttccag atgaaggacc agctggataa cctgctgctg aaggagagcc tgctggagga cttcaagggc tacctgggct gccaggccct gagcgagatg atccagttct acctggagga ggtgatgccc 960 caggccgaga accaggaccc cgacatcaag gcccacgtga acagcctggg cgagaacctg aagaccctga ggctgaggct gaggaggtgc cacaggttcc tgccctgtga gaacaaatcc aaggccgtgg agcaggtgaa gaacgccttc aacaagctgc aggaaaaggg catctacaag 1140 gccatgagcg agttcgacat ctttatcaac tatatcgagg cctacatgac aatgaagatc 1200 aggaacggcg gcggcggcag cgggggcggc ggcagcggag gaggcggcag cagccccggc 1260 cagggcacac agtccgagaa cagctgcacc cactttcccg gcaacctgcc taacatgctg 1320 agggacctga gggacgcctt cagcagggtg aagaccttct tccagatgaa ggaccagctg 1380 gataacctgc tgctgaagga gagcctgctg gaggacttca agggctacct gggctgccag 1440 gccctgagcg agatgatcca gttctacctg gaggaggtga tgccccaggc cgagaaccag 1500 gaccccgaca tcaaggccca cgtgaacagc ctgggcgaga acctgaagac cctgaggctg 1560 aggctgagga ggtgccacag gttcctgccc tgtgagaaca aatccaaggc cgtggagcag 1620 gtgaagaacg ccttcaacaa gctgcaggaa aagggcatct acaaggccat gagcgagttc 1680 gacatcttta tcaactatat cgaggcctac atgacaatga agatcaggaa c 1731 <210> 62 <211> 402 <212> PRT <213> Artificial Sequence <220> <223> Fc6-IL10 amino acid sequence <400> 62 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Gly Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Lys Leu Ala Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His 245 250 255 Phe Pro Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe 260 265 270 Ser Arg Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu 275 280 285 Leu Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys 290 295 300 Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro 305 310 315 320 Gln Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu 325 330 335 Gly Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg 340 345 350 Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn 355 360 365 Ala Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu 370 375 380 Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile 385 390 395 400 Arg Asn <210> 63 <211> 1206 <212> DNA <213> Artificial Sequence <220> <223> Fc6-IL10 gene <400> 63 gacaaaactc acacatgccc accgtgccca gctccggaac tcctgggcgg accgtcagtc 60 ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 120 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac 180 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtatacc ctgcccccat cccgggatga gctgaccaag 420 aaccaggtca gcctgagttg cggggtcaaa ggcttctatc ccagcgacat cgccgtggag 480 tgggagagca atgggcagcc ggagacac tacaagacca cgcctcccgt gttggactcc 540 gacggctcct tcaagctcgc cagcaagctc accgtggaca agagcaggtg gcagcagggg 600 aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacc gcagaagagc ctctccctgt ctccgggtaa aggaggtggc ggatcggggag gcggtgggag tggcggtgga 720 ggatccagcc ccggccaggg cacacagtcc gagaacagct gcacccactt tcccggcaac 780 840. ctgcctaaca tgctgaggga cctgagggac gccttcagca gggtgaagac cttcttccag atgaaggacc agctggataa cctgctgctg aaggagagcc tgctggagga cttcaagggc 900 tacctgggct gccaggccct gagcgagatg atccagttct acctggagga ggtgatgccc 960 caggccgaga accaggaccc cgacatcaag gcccacgtga acagcctggg cgagaacctg 1020 aagaccctga ggctgaggct gaggaggtgc cacaggttcc tgccctgtga gaacaaatcc 1080 aaggccgtgg agcaggtgaa gaacgccttc aacaagctgc aggaaaaggg catctacaag 1140 gccatgagcg agttcgacat ctttatcaac tatatcgagg cctacatgac aatgaagatc 1200 page 1206 <210> 64 <211> 402 <212> PRT <213> Artificial Sequence <220> <223> Fc-IL10 <400> 64 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His 245 250 255 Phe Pro Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe 260 265 270 Ser Arg Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu 275 280 285 Leu Leu Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys 290 295 300 Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro 305 310 315 320 Gln Ala Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu 325 330 335 Gly Glu Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg 340 345 350 Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn 355 360 365 Ala Phe Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu 370 375 380 Phe Asp Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile 385,390,395,400 Arg Asn <210> 65 <211> 1206 <212> DNA <213> Artificial Sequence <220> <223> Fc-IL10 <400> 65 gacaagaccc acacctgccc cccctgcccc gccccgagc tgctgggcgg ccccagcgtg 60 ttcctgttcc cccccaagcc caaggacacc ctgatgatca gccgcacccc cgaggtgacc 120 tgcgtggtgg tggacgtgag ccacgagaac cccgaggtga agttcaactg gtacgtggac 180 ggcgtggagg tgcaacgc caagaccaag ccccgcgagg agcagtacaa cagcacctac 240 cgcgtggtga gcgtgctgac cgtgctgcac caggactggc tgaacggcaa ggagtacaag 300 tgcaaggtga gcaacaagc cctgcccgcc cccatcgaga agaccatcag caaggccaag 360 ggccagcccc gcgagcccca ggtgtacacc ctgcccccca gccgcgacga gctgaccaag 420 aaccaggtga gcctgacctg cctggtgaag ggcttctacc ccagcgacat cgccgtggag 480 tgggagagca acggccagcc cgagaacaac tacaagacca ccccccccgt gctggacagc 540 gacggcagct tcttcctgta cagcaagctg accgtggaca agagccgctg gcagcagggc 600 aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagagc 660 ctgagcctga gccccggcaa gggaggtggc ggatcgggag gcggtgggag tggcggtgga 720 ggatccagcc ccggccaggg cacacagtcc gagaacagct gcaccactt tcccggcaac 780 ctgcctaaca tgctgaggga cctgagggac gccttcagca gggtgaagac cttcttccag 840 atgaaggacc agctggataa cctgctgctg aaggagagcc tgctggagga cttcaagggc 900 tacctgggct gccaggccct gagcgagatg atccagttct acctggagga ggtgatgccc 960 1020 aagaccctga ggctgaggct gaggaggtgc cacaggttcc tgccctgtga gaacaaatcc 1080 aaggccgtgg agcaggtgaa gaacgccttc aacaagctgc aggaaaaggg catctacaag 1140 gccatgagcg agttcgacat ctttatcaac tatatcgagg cctacatgac aatgaagatc 1200 aggaac 1206 <210> 66 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Hinge region amino acid sequence <400> 66 Glu Pro Lys Ser Ser 1 5
Claims
1. A protein heterodimer comprising a first monomer member and a second monomer member different from the first monomer member, wherein: The first monomer member includes a first Fc subunit, the second monomer member includes a second Fc subunit, and the first monomer member associates with the second monomer member to form the heterodimer through the complexing of the first Fc subunit and the second Fc subunit; wherein the protein heterodimer further includes one or more IL10s directly or indirectly fused to the carboxyl terminal amino acids of the first Fc subunit or the second Fc subunit; and wherein the protein heterodimer does not include any antibody heavy chain variable region or any antibody light chain variable region that exhibits binding specificity to a tumor antigen, the amino acid sequence of the first monomer member is as shown in SEQ ID NO.17, and the amino acid sequence of the second monomer member is as shown in any one of NO.55 and NO.
60.
2. One or more isolated nucleic acids encoding the protein heterodimer according to claim 1.
3. One or more vectors comprising one or more isolated nucleic acids according to claim 2.
4. An isolated host cell comprising one or more isolated nucleic acids according to claim 2 or one or more vectors according to claim 3.
5. A protein mixture comprising: 1) The protein heterodimer according to claim 1; 2) A protein heterodimer according to claim 1, wherein the first homodimer is formed by two identical copies of the first monomer member, the protein heterodimer comprising a first monomer member and a second monomer member different from the first monomer member, wherein: the first monomer member comprises a first Fc subunit, the second monomer member comprises a second Fc subunit, and the first monomer member associates with the second monomer member to form the heterodimer by complexing the first Fc subunit with the second Fc subunit; wherein the protein heterodimer further comprises one or more IL10s fused directly or indirectly to the carboxyl terminal amino acids of the first Fc subunit or the second Fc subunit; and wherein the protein heterodimer does not include any antibody heavy chain variable region or any antibody light chain variable region that exhibits binding specificity to a tumor antigen, and the amino acid sequence of the first monomer member is as shown in SEQ ID NO.17, the amino acid sequence of the second monomer member is as shown in any one of NO.55 and NO.60; and 3) the protein heterodimer according to claim 1, wherein the second homodimer formed by two identical copies of the second monomer member, the protein heterodimer comprises a first monomer member and a second monomer member different from the first monomer member, wherein: the first monomer member comprises a first Fc subunit, the second monomer member comprises a second Fc subunit, and the first monomer member associates with the second monomer member to form the heterodimer through the complexing of the first Fc subunit and the second Fc subunit; wherein the protein heterodimer further comprises one or more IL10s directly or indirectly fused to the carboxyl terminal amino acids of the first Fc subunit or the second Fc subunit; and wherein the protein heterodimer does not include any antibody heavy chain variable region or any antibody light chain variable region that exhibits binding specificity to a tumor antigen, and the amino acid sequence of the first monomer member is as shown in SEQ ID As shown in NO.17, the amino acid sequence of the second monomer member is as shown in any one of NO.55 and NO.60; wherein the percentage of the protein heterodimer in the protein mixture is at least 50%.
6. The protein mixture according to claim 5, wherein The percentage of the second homodimers is less than the percentage of the first homodimers.
7. The protein mixture according to claim 5, wherein The percentage of the second homodimer is at most 10%.
8. The protein mixture according to claim 5, wherein The protein mixture does not include the second homodimer.
9. The protein mixture according to any one of claims 5 to 8, wherein The protein mixture is directly produced by the host cell without enrichment of the protein heterodimer or depletion of the first or the second homodimer.
10. The protein mixture according to any one of claims 5 to 8, wherein The protein mixture is directly produced by host cells without enrichment of the protein heterodimers and without removal of the first or the second homodimers.
11. A pharmaceutical composition comprising the protein heterodimer according to claim 1, or the protein mixture according to any one of claims 5 to 10, and optionally a pharmaceutically acceptable excipient.
12. The pharmaceutical composition according to claim 11, wherein The protein heterodimer is formulated for oral administration, intravenous administration, intramuscular administration, in situ administration at a tumor site, inhalation, rectal administration, vaginal administration, transdermal administration, or administration via a subcutaneous depot.
13. Use of the protein heterodimer according to claim 1 or the protein mixture according to any one of claims 5 to 10 for preparing a medicament for inhibiting the growth of a tumor or tumor cells, wherein the tumor is melanoma.
14. Use of the protein heterodimer according to claim 1 or the protein mixture according to any one of claims 5 to 10 for the preparation of a medicament for treating cancer in a subject in need thereof, wherein the cancer is melanoma.
